[User]
<|image|>Continue parse the picture with markdown style: <md> | Predictor | β | 95% CI | P-value |
 | --- | --- | --- | --- |
 | Constant | −0.17 | −0.21, −0.13 | <0.01 |
 | Maternal Blood Lead (MBL) | 0.92 | 0.82, 1.03 | <0.01 |
 | Maternal TF P570S | 0.04 | −0.03, 0.11 | 0.28 |
 | MBL × Maternal TF P570S | −0.13 | −0.35, 0.09 | 0.24 |
 | Maternal HFE H63D | −0.07 | −0.14, 0.01 | 0.08 |
 | MBL × Maternal HFE H63D | −0.12 | −0.34, 0.11 | 0.32 |
 | Maternal HFE C282Y | −0.002 | −0.09, 0.09 | 0.97 |
 | MBL × Maternal HFE C282Y | −0.27 | −0.52, −0.01 | 0.04 |
 | Infant TF P570S | −0.06 | −0.13, 0.003 | 0.06 |
 | MBL × Infant TF P570S | −0.03 | −0.24, 0.18 | 0.81 |
 | Infant HFE H63D | 0.01 | −0.06, 0.08 | 0.77 |
 | MBL × Infant HFE H63D

[Assistant]
| 0.10 | −0.11, 0.32 | 0.34 |
 | Infant HFE C282Y | −0.02 | −0.11, 0.07 | 0.65 |
 | MBL × Infant HFE C282Y | −0.05 | −0.28, 0.17 | 0.64 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | Participants, N and location | Interview type | Core areas explored |
 | --- | --- | --- |
 | Sample 1. Depressed pregnant adolescents, (N = 8 from Kariobangi site) | Key informant interviews | Their personal/emotional experiences, relationships, and circumstances of pregnancy, family and social support available, interface with health facility, plans for future |
 | Sample 2. Caregivers of pregnant adolescents (N = 6 from both sites) | Key informant interviews | Their reaction to the pregnancy, resources available to support the adolescent, plans for future for adolescent and the baby, support from community and CHWs |
 | Sample 3. (i) Follow-up from sample 1: new adolescent mothers who gave birth,

[Assistant]
(N = 9 from both sites); (ii) new adolescent mothers: (N = 13 from Kariobangi site) | (i) Key informant interviews(ii) One focused group discussion | Reflecting on their experience of pregnancy, evaluation of support available from family, partner, health facility, and CHWs. Knowledge about adolescent pregnancy, their mental health problems, referrals and support available to them and their caregivers, challenges in working with this group |
 | Sample 4. HW, CHWs, MCH staff/medical staff, (N = 20 from both sites) | Two focused group discussions | Experience and knowledge about adolescent pregnancy and their mental health problems, referrals and health facility support and engagement, challenges in being a bridge between families and the health care system | </md>


[User] <|image|>Render the illustration in Markdown format.

[Assistant]
<md> |  | Investigator 1(analysis 1) | Investigator 1(analysis 2) | Investigator 2 |
 | --- | --- | --- | --- |
 | Inflow | 68 ± 11 | 71 ± 9 | 72 ± 12 |
 | Outflow | 67 ± 13 | 69 ± 13 | 70 ± 15 |
 | P-value | NS | NS | NS | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Reduced joint score | Joints, tendons and bursae included |
 | --- | --- |
 | 7-joint score [9] | On the clinically dominant side:Wrist, MCP 2 and 3, PIP 2 and 3, MTP 2 and 5Dorsal, ulnar and palmar tendon sheaths of the wrist, flexor tendon sheaths of 2 and 3 finger, paratendonitis dorsal 2 and 3 finger |
 | 12-joint score [10] | Bilateral examination of:Elbow, wrist, MCP 2 and 3, knee and ankleMedial and lateral tendon sheaths of the ankle |
 | 28-joint score [12] | Bilateral examination of:Shoulder (glenohumeral), elbow, wrist, MCP 1 to 5, PIP 1 to 5 and knee

[Assistant]
|
 | 44-joint score [10] | Bilateral examination of:Shoulder (glenohumeral), elbow, wrist, MCP 1 to 5, PIP 1 to 5, hip, knee, ankle, mid-tarsal, MTP 1 to 5Biceps tendon sheath, extensor and flexor tendons sheaths of the wrist, flexor tendons sheaths of the fingers, anterior, medial and lateral tendon sheaths of the ankleSubdeltoid bursa | </md>


[User] <|image|>Translate the photo into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Locus | <COLSPAN=2> Tajima's D | <COLSPAN=2> Fu and Li's F* | <COLSPAN=2> Ramos‐Onsins and Rozas R2 |
 | I. spurius | I. fuertesi | I. spurius | I. fuertesi | I. spurius | I. fuertesi |
 | --- | --- | --- | --- | --- | --- | --- |
 | CR‐ mtDNA | −1.965* | −1.349 | −2.271 | −1.351 | 0.054 | 0.166 |
 | GADPH11 | −0.046 | 1.0921 | −0.637 | 1.375 | 0.101 | 0.177 |
 | TGFB2 | −1.276 | −1.008 | −2.264 | −2.098 | 0.067 | 0.091 |
 | RDP2 | −0.052 | −0.059 | −0.471 | 0.354 | 0.109 | 0.124 |
 | SLC9 | −1.965 | 1.014 | 0.152 | 1.309 | 0.087 | 0.186 | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> |  |  |  | <COLSPAN=2> Cell Viability |
 | --- | --- | --- | --- | --- |
 |

[Assistant]
| Compound | Dose | Human Non-small Cell Lung Cancer | Normal Diploid Fibroblasts |
 | XVI. (THR53) | Cyc-[FPPRGPRPVKLALKLALK] | 200 μM | _ _ _ | + + + |
 | XVII. (THR53C) | Cyc-[FPPRRPGPVKLALKLALK] | 200 μM | + + + | + + + |
 | XVIII. (THR54) | Cyc-[PRGPRPVALKLALKLAL] | 100 μM | _ _ _ | + + + |
 | XIX. (THR79) | Cyc-[PRGPRPvalklalklal] | 50 μM | _ _ _ | + + + |
 | XX. | Cyc-[PR(Me)GPRPVALKLALKLAL] | 200 μM | + +/- | N/D |
 | XXI. | Cyc-[PRGPR(Me)PVALKLALKLAL] | 200 μM | ++ + | N/D |
 | XII. | Cyc-[PR(Me)GPR(Me)PVALKLALKLAL] | 200 μM | + + + | N/D | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Item | Patients |
 | --- | --- |
 | Age (y) | 69.7 ± 9.4 |
 | Male/Female | 31/9 |
 | Weight (Kg) | 77 ± 9.5 |
 | BMI (Kg/m2) | 47.1 ± 4.8 |
 | Obesity (BMI > 30 Kg/m2) | 27 (67.5%) |
 | Hypertension | 27 (67.5%) |
 |

[Assistant]
Diabetes | 14 (35%) |
 | Smoking | 10 (25%) |
 | Hypothyroidism | 2 (5%) |
 | Chronic Renal Failure | 11 (27.5%) |
 | COPD | 8 (20%) |
 | PVD | 1 (2.5%) |
 | Corticosteroid use | 1 (2.5%) |
 | CHF | 10 (25%) |
 | Re-operation | 3 (7.5%) | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | <COLSPAN=2> Model 1 | <COLSPAN=2> Model 2 | <COLSPAN=2> Model 3 |
 |  | OR (95 % CI) | P | OR (95 % CI) | P | OR (95 % CI) | P |
 | --- | --- | --- | --- | --- | --- | --- |
 | Snoring status |  |  |  |  |  |  |
 | Non-snorers | 1.000 (reference) |  | 1.000 (reference) |  | 1.000 (reference) |  |
 | Snorers | 1.734 (1.522–1.976) | <0.001 | 1.709 (1.495–1.953) | <0.001 | 1.371 (1.147–1.637) | <0.001 |

[Assistant]
| Snoring intensity |  |  |  |  |  |  |
 | Non-snorers | 1.000 (reference) |  | 1.000 (reference) |  | 1.000 (reference) |  |
 | Low | 1.352 (1.111–1.644) | 0.003 | 1.381 (1.131–1.687) | 0.002 | 1.094 (0.834–1.434) | 0.518 |
 | Normal | 1.767 (1.477–2.115) | <0.001 | 1.774 (1.476–2.133) | <0.001 | 1.436 (1.126–1.832) | 0.004 |
 | Strong | 2.025 (1.666–2.460) | <0.001 | 1.886 (1.545–2.302) | <0.001 | 1.462 (1.124–1.902) | <0.001 |
 | Very strong | 2.344 (1.745–3.149) | <0.001 | 2.199 (1.624–2.977) | <0.001 | 1.813 (1.273–2.684) | <0.001 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> |  | Casein diet | Chungkookjang (CKJ) diet | Jerusalem artichoke (HTL) diet | CKJ+HTL diet |
 | --- | --- | --- | --- | --- |
 | Casein (g) | 200 | 183 | 197 | 183 |
 | Methionine (g) | 3 | 3 | 3 | 3 |
 | Corn starch (g) | 300 | 295 | 273 | 260 |
 | Sucrose (g) | 200 | 200 | 200 | 200 |
 | Cellulose (g) | 34 | 14 | 14 | 0 |
 | Corn oil (g) | 50 | 44 | 50 | 43 |
 | Shortening (g) | 150 |

[Assistant]
150 | 150 | 150 |
 | Mineral (g) | 35 | 33 | 35 | 33 |
 | Vitamin (g) | 10 | 10 | 10 | 10 |
 | Choline (g) | 2 | 2 | 2 | 2 |
 | Powder of CKJ (g) | 0 | 50 | 0 | 50 |
 | Powder of HTL (g) | 0 | 0 | 50 | 50 |
 | Total isoflavonoids (%) | - | 0.013 | - | 0.013 |
 | Isoflavonoid aglycones (%) | - | 0.012 | - | 0.012 |
 | Fructooligossaccharides including inulin (%) |  |  | 1.5 | 1.5 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | Test Enrollment | Conventional | EDoF | EdoF with Wiener |
 | --- | --- | --- | --- |
 | <ROWSPAN=4> Conventional | DoF = 6 cm | DoF = 18.4 cm | DoF = 0 cm |
 | SI = 4.3 | SI = 4.5 | SI = 3.3 |
 | FRR = 4.7% | FRR = 17.5% | FRR = 53.3% |
 | EER = 1.0% | EER = 2.9% | EER = 7.0% |
 | <ROWSPAN=4> EdoF | <ROWSPAN=4>  | DoF = 22.2 cm | DoF = 4.5 cm |
 | SI = 4.0 | SI = 2.8 |
 | FRR = 23.0% | FRR = 18.3% |
 | EER = 3.3% | EER = 3.3% |
 | <ROWSPAN=4> EdoF with Wiener | <ROWSPAN=4>  | <ROWSPAN=4>  | DoF = 18.6 cm |
 | SI = 3.9 |
 | FRR = 23.3% |
 | EER = 3.3% | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Crude associations | <COLSPAN=2> Model 2.1 | <COLSPAN=2> Model 2.2 | <COLSPAN=2> Model 2.3 |
 |  | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR |  |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Gender: female | 1.169 | (0.705; 1.938) | 1.130 | (0.658; 1.942) | 1.291 | (0.742; 2.246) | 1.238 | (0.707; 2.170) |
 | Age | 1.045 | (0.986; 1.108) | 1.056 | (0.993; 1.124) | 1.058 | (0.993; 1.127) | 1.072* | (1.004; 1.144) |
 | Low educational level | 1.658* | (1.008; 2.728) | 1.577 | (0.931; 2.672) | 1.543 | (0.907; 2.624) | 1.640 | (0.943; 2.852) |
 | Health-related behaviour | 0.686** | (0.524; 0.898) |  |  | 0.678** | (0.511; 0.901) | 0.678** | (0.507; 0.905) |
 | Physical demands | 1.141 | (0.993; 1.312) |  |  |  |  | 1.007 | (0.856; 1.185) |
 | Psychological job demands | 1.673*** | (1.268; 2.207) |  |  |  |  | 1.438* | (1.017; 2.033) |
 | Job control | 0.565** | (0.383; 0.834) |  |  |  |  | 0.590* | (0.391; 0.892) |
 | ERI: ER ratio > 1 | 3.197*** | (1.800; 5.678) | 3.374*** | (1.881; 6.051) | 3.334*** | (1.852; 6.002) | 2.093* | (1.047; 4.183) |
 | N-R2 |  |  | 0.063 |  | 0.084 |  | 0.117 |  | </md>


[User] <|image|>Convert the diagram into Markdown language.

[Assistant]
<md> | Substrate | Enzyme Added (ng) | Specific Activity μmol/min/mg a |
 | --- | --- | --- |
 | 2-Oxoglutaramate (2-OGM) b | 72.8 | 3.0 ± 0.9 (3) |
 | Succinamate c | 146 | 3.4 ± 0.3 (3) |
 | l-2-Hydroxyglutaramate (l-2-HGM) c | 291 | 1.4 ± 0.1 (7) |
 | l-2-Hydroxysuccinamate (l-2-HSM) d | 146 | 0.51 ± 0.18 (5) | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Group | HR/min | MAP (mmHg) | +dP/dtmax | −dP/dtmax |
 | --- | --- | --- | --- | --- |
 | Sham operated | 420.31 ± 17.41 | 134.44 ± 4.91 | 6145.63 ± 348.09 | 4903.41 ± 278.45 |
 | CA model | 336.63 ± 20.31∗∗ | 94.62 ± 7.64∗∗ | 3533.01 ± 135.81∗∗ | 2698.25 ± 199.32∗∗ |
 | CA + low dose | 391.34 ± 18.76‡ | 103.71 ± 4.92 | 3865.41 ± 219.76† | 2937.49 ± 301.76† |
 | CA + medium dose | 394.20 ± 17.76‡ | 105.29 ± 6.29 | 3904.03 ± 178.62‡§ | 3231.01 ± 210.93‡§ |
 | CA + high dose | 408.54 ± 16.29‡ | 114.94 ± 7.09‡§†† | 4376.29 ± 185.73‡¶‡‡ | 3813.13 ± 108.82‡¶‡‡ | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | Receiver | Male | Female | Chi square | P |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=6> Female giver | Father/mother | 15 | 75 | 40 | <0.001 |
 | Brother/sister | 42 | 63 | 4.2 | 0.04 |
 | Son/daughter | 46 |

[Assistant]
50 | 0.167 | 0.683 |
 | Brother’s/sister’s children | 4 | 22 | 12.462 | <0.001 |
 | Son’s/daughter’s children | 1 | 13 | 10.286 | 0.001 |
 | Other males/females | 95 | 220 | 49.603 | <0.001 |
 | <ROWSPAN=6> Male giver | Father/mother | 10 | 38 | 16.333 | <0.001 |
 | Brother/sister | 19 | 35 | 4.741 | 0.029 |
 | Son/daughter | 15 | 20 | 0.741 | 0.398 |
 | Brother’s/sister’s children | 3 | 17 | 9.8 | 0.002 |
 | Son’s/daughter’s children | 0 | 2 | n/a | n/a |
 | Other males/females | 172 | 109 | 14.125 | <0.001 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | IL-26 (ng/ml) Uncontrolled asthma | n | IL-26 (ng/ml) Controlled asthma | n | p-value* |
 | --- | --- | --- | --- | --- | --- |
 | All patients | 4.4 (1.9–14) | 48 | 2.4 (1.3–4.5) | 28 | 0.077 |
 | Low B-EOS (≤ 0.3×109/L) | 4.6 (2.3–13) | 27 | 2.3 (1.3–4.5) | 22 | 0.038* |
 | High B-EOS (>0.3×109/L) | 4.1 (1.7–16) | 21 | 2.9 (1–31) |

[Assistant]
5 | 0.61 |
 | Low FENO (≤18.3 p.p.b.) | 4.1 (2.2–16) | 23 | 2.0 (1.2–3.6) | 13 | 0.055 |
 | High FENO (>18.3 p.p.b) | 5.0 (1.8–13) | 25 | 2.7 (1.4–24) | 15 | 0.54 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  | BC4CHEMD | BC2GM | AnatEM | JNLPBA |
 | --- | --- | --- | --- | --- |
 | UMN-rel | -0.15 | -0.14 | -0.08 | -0.07 |
 | UMN-sim | -0.38 | -0.34 | -0.34 | -0.3 |
 | MayoSRS | 0.08 | 0.04 | 0.18 | 0.12 |
 | Bio-SimVerb | 0.2 | 0.18 | 0.29 |

[Assistant]
0.24 |
 | Bio-SimLex | 0.53 | 0.6 | 0.46 | 0.48 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Characteristic | n | <COLSPAN=3> Radiotherapy | p |
 |  |  | No (%) | Preoperative (%) | Postoperative (%) |  |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Sex |
 | Male | 198 | 35 (66.0) | 89 (64.5) | 74 (73.3) | 0.341 |
 | Female | 94 | 18 (34.0) | 49 (35.5) | <COLSPAN=2> 27 (26.7) |
 | <COLSPAN=6> Age |
 | Mean ± SD (years) | 57 ± 16.8 | 67 ± 17.2 | 54 ± 16.3 | 55 ± 15.2 | <0.001 |
 | Race |  |  |  |  |  |
 | White | 224

[Assistant]
| 40 (75.5) | 99 (71.7) | 85 (84.2) | 0.095 |
 | Black | 23 | 5 (9.4) | 10 (7.2) | 8 (7.9) |  |
 | Other and unknown | 45 | 8 (15.1) | 29 (21.0) | 8 (7.9) |  |
 | <COLSPAN=6> Tumor grade |
 | G1–2 | 20 | 3 (5.7) | 7 (5.1) | 10 (9.9) | 0.118 |
 | G3–4 | 237 | 47 (88.7) | 108 (78.3) | 82 (81.2) |  |
 | Unknown | 35 | 3 (5.7) | 23 (16.7) | 9 (8.9) |  |
 | <COLSPAN=6> Tumor size (mm) |
 | Mean ± SD | 53.5 ± 25.1 | 55.4 ± 26.6 | 53.3 ± 25.6 | 52.8 ± 23.9 | 0.835 |
 | Number of RLNs (n) |  |  |  |  |  |
 | Mean ± SD | 14.8 ± 11.6 | 13.3 ± 10.0 | 13.9 ± 10.1 | 16.9 ± 13.9 | 0.080 |
 | Number of PLNs (n) |  |  |  |  |  |
 | Mean ± SD | 6.7 ± 7.2 | 8.3 ± 9.2 | 5.2 ± 5.8 | 7.9 ± 7.2 | 0.003 |
 | <COLSPAN=6> Tumor stage |
 | II | 51 | 11 (20.8) | 29 (21.0) | 11 (10.9) | 0.099 |
 | III | 241 | 42 (79.2) | 109 (79.0) | <COLSPAN=2> 90 (89.1) | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | Method | Cohen's kappa | Sensitivity | Specificity |
 | --- | --- | --- | --- |
 | FISH versus CB11 | 83.0% (SE 5.3%) | 97% | 93% |
 | HercepTest versus FISH |  |  |  |
 | (0–1 versus 2–3) versus FISH | 72.0% (SE 6.2%) | 92% | 87%

[Assistant]
|
 | (0–2 versus 3) versus FISH | 79.2% (SE 6.0%) | 78% | 97% |
 | HercepTest versus CB11 |  |  |  |
 | (0–1 versus 2–3) versus CB11 | 70.0% (SE 6.3%) | 100% | 85% |
 | (0–2 versus 3) versus CB11 | 84.2% (SE 5.4%) | 90% | 96% | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <ROWSPAN=2> Variable | <COLSPAN=2> Urinary tract infection | <ROWSPAN=2> Odds ratio | <ROWSPAN=2> Confidence interval | <ROWSPAN=2> P-value |
 | yes | No |
 | --- | --- | --- | --- | --- | --- |
 | Age | 64.503±18.66 | 61.26±19.47 | - | 0.619-5.857 | 0.015 |
 | Time of catheterization | 11.67 ± 17.65 |

[Assistant]
7.69 ± 7.29 | - | 1.739-6.218 | 0.001 |
 | Gender |  |  |  |  |  |
 | MaleFemale | 116(14.7%)140(22.7%) | 675(47.9%)478(33.9%) | 0.587 | 0.447–0.771 | 0.001 |
 | Perineal care |  |  |  |  |  |
 | YesNo | 229(18.3%)11(0.9%) | 875(69.4%)145(11.5%) | 3.450 | 1.837–6.477 | 0.001 |
 | History of underlying disease |  |  |  |  |  |
 | YesNo | 131(10.5%)106(805%) | 476(38.2%)534(42.4%) | 11.386 | 1.043–1.842 | 0.004 |
 | Antibiotic therapy before catheterization |  |  |  |  |  |
 | YesNo | 126(9.7%)115(8.9%) | 577(44.5%)478(36.9%) | 0.908 | 0.686-1.201 | 0.004 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | <COLSPAN=2> Characteristic | Thyroid gland invasion | No thyroid gland invasion | P-value |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=2> Age (mean±SD) | 61.00±9.69 | 60.97±8.71 | 0.99 |
 | <ROWSPAN=2> Gender (n,%) | Male | 10 (83.3%) | 43 (89.5%) | <ROWSPAN=2> 0.61 |
 | Female | 2 (16.7%) | 5 (10.5%) |
 | <ROWSPAN=2> T subtype (n,%) | T3 | 11 (91.7%) | 29 (60.5%) | <ROWSPAN=2> 0.04 |
 | T4 | 1 (8.3%) | 19 (39.5%) |
 | <ROWSPAN=2> Grade (n,%) | Well differentiated | 11 (91.7%) | 25 (52%) | <ROWSPAN=2> 0.01 |
 | Moderately well differentiated | 1 (8.3%) | 23 (48%) |
 | <COLSPAN=2> Largest dimension of the tumor (mean±SD) | 6.50±1.69 | 4.96±1.36 | 0.004 |
 | <ROWSPAN=3> Site of laryngeal tumor (n, %) | Transglottic | 6 (50%) | 40 (83.4%) | <ROWSPAN=3> 0.008 |
 | Supraglottic | 4 (33.4%) | 4 (8.3%) |
 | Glottic | 2 (16.6%) | 4 (8.3%) |
 | <ROWSPAN=3> Thyroid surgery | TT | 4 (33.4%) | 20 (41.5%) | <ROWSPAN=3> 0.86 |
 | L | 7 (58.3%) | 23 (48%) |
 | PL | 1 (8.3%) | 5 (10.5%) | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Movement disorder | Treatment category | Treatment specifics | N | Positive effect (n) |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Dystonia |
 |  | Pharmacological |  |  |  |
 |  |  | Clonazepam | 1 | 1 |

[Assistant]
 |  |  | Gabapentin | 3 | 3 |
 |  |  | L-dopa | 2 | 1 |
 |  |  | Trihexyphenidyl | 8 | 3 |
 |  |  | Cessation of drug | 1 | 1 |
 |  | Botulinum toxin |  | 5 | 5 |
 |  | Deep brain stimulation |  | 5 | 4 |
 |  | Paramedical |  | 2 | 2 |
 |  | Total dystonia |  | 27 | 20 |
 | <COLSPAN=5> Myoclonus |
 |  | Pharmacological | Clonazepam | 10 | 10 |
 |  | Ketogenic diet |  | 4 | 1 |
 |  | Paramedical |  | 4 | 2 |
 |  | Total myoclonus |  | 18 | 12 |
 | <COLSPAN=5> Other |
 |  | Pharmacological |  |  |  |
 |  |  | L-dopa | 4 | 4 |
 |  |  | Acetozolamide | 1 | 1 |
 |  |  | Cessation of drug | 4 | 2 |
 |  | Botulinum toxin |  | 1 | 1 |
 |  | Paramedical |  | 3 | 2 |
 |  | Total other |  | 13 | 10 |
 | <ROWSPAN=2> Difficult to classify |  |  | 2 |  |
 | Pharmacological | L-dopa | 2 | 1 |
 | Total |  |  | 60 | 43 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Angle’s malocclusion | N (%) | P-value (Chi-Square) |
 | --- | --- | --- |
 | <COLSPAN=2> Occlusal traits |  |
 | Angle’s Class 1 | 264 (52.8%) | <ROWSPAN=3> < 0.001 |
 | Angle’s Class 2 | 159 (31.8%) |
 | Angle’s Class 3 | 77 (15.4%) |
 | <COLSPAN=2> Overjet |  |
 | Normal | 332 (66.4%) | <ROWSPAN=3> < 0.001 |
 | Excessive | 111 (22.2%) |
 | Reduced | 57 (11.4%) |
 | <COLSPAN=2> Overbite |  |
 | Normal | 322 (64.4%) | <ROWSPAN=3> < 0.001 |
 | Excessive | 117 (23.4%) |
 | Reduced | 61 (12.2%) |
 | <COLSPAN=2> Crowding |  |
 | Present | 236 (47.2%) | <ROWSPAN=2> 0.8944 |
 |

[Assistant]
Absent | 264 (52.8%) |
 | <COLSPAN=2> Spacing |  |
 | Present | 136 (27.2%) | <ROWSPAN=2> < 0.001 |
 | Absent | 364 (72.8%) |
 | <COLSPAN=2> Anterior crossbite |  |
 | Present | 24 (4.8%) | <ROWSPAN=2> < 0.001 |
 | Absent | 476 (95.2%) |
 | <COLSPAN=2> Posterior crossbite |  |
 | Present | 47 (9.4%) | <ROWSPAN=2> < 0.001 |
 | Absent | 453 (90.6%) |
 | <COLSPAN=2> Open bite |  |
 | Present | 23 (4.6%) | <ROWSPAN=2> < 0.001 |
 | Absent | 477 (95.4%) |
 | <COLSPAN=2> Facial Profile |  |
 | Straight | 246 (49.2%) | <ROWSPAN=3> < 0.001 |
 | Convex | 213 (42.6%) |
 | Concave | 41 (8.2%) | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> |  | Oldest third (n = 2219) | Middle third (n = 2160) | Youngest third (n = 2373) |
 | --- | --- | --- | --- |
 | Year of birth |  |  |  |
 | 1984 cohort | 45.1 | 48.1 | 47.3 |
 | 1985 cohort | 50.8 | 49.9 | 49.0 |
 | Gender |  |  |  |
 | Female | 49.9 | 51.9 | 49.9 |
 | Ethnicity |  |  |  |
 | Minority groups | 22.8 | 24.4 | 25.4 |
 | Parental educational level |  |  |  |
 | Higher university | 16.9 | 17.7 | 17.8 |
 | Lower university | 26.6 | 26.0 | 27.9 |
 | Secondary | 37.4 | 37.9 | 36.5 |
 | Missing | 19.0 | 18.5 | 17.8 |
 | Social support |  |  |  |
 | Family low | 43.8 | 41.5 | 41.6 |
 | Class low | 36.5 | 36.0 | 35.5 |
 | Teachers low | 41.5 | 41.4 | 39.2 |
 | Friends low | 43.1 | 41.5 | 40.9 | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> |  | n = 1681 |
 | --- | --- |
 | Age group, y, n (%) |  |
 | · <20 | 60 (3.6) |
 | · 20–39 | 287 (17.0) |
 | · 40–59 | 516 (30.7) |
 | · 60–79 | 734 (43.7) |
 | · 80+ | 84 (5.0)

[Assistant]
|
 | Mean age (SD) | 55.3 (17.8) |
 | Male/Female, n (%) | 729 (43.4)/952(56.6) |
 | Rate of comorbidities, n (%) |  |
 | · Hypertension | 842 (50.1) |
 | · Heart disease | 695 (41.3) |
 | · Respiratory illness | 570 (33.9) |
 | · Diabetes | 549 (32.7) | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | Regulators | Target genes | Anti-cancer drugs | Cell or tissue types | Function | Effect | References |
 | --- | --- | --- | --- | --- | --- | --- |
 | HuR | ER | Tamoxifen | Breast cancer cell | mRNA stability ↑ | Resistance ↑ | [13] |
 | HuR | COX-2 | Lapatinib | Breast cancer cell | mRNA stability ↑ | Invasion ↑Metastasis ↑ | [19] |
 | HuR | TGIF | ATO | Hepatocellular carcinoma cell | mRNA stability ↑ | Cell death ↓ | [16] |
 | HuR | dCK | Gemcitabine | Pancreatic cancer | Translation ↑ | Sensitivity ↑ | [17] |
 | HuR | BCL2 | Etoposide, Topotecan, Cisplatin | Glioma cell | Translation ↑ | Resistance ↑ | [21] |
 | HuR | TOP2A | Doxorubicin | Hela cell | Translation ↑ | Sensitivity ↑ | [25] |
 | HuR | Several targets | Doxorubicin | Breast cancer cell | Translation ↑ | Sensitivity ↑ | [24] |
 | HuR | Beta-tubulin | Cisplatin | Ovarian cancer cells | Translation ↑ | Resistance ↑ | [22] |
 | RBM3 | Unknown | Cisplatin | Epithelial ovarian cancer | Unknown | Sensitivity ↑ | [28] |
 | RBM5 | Unknown | Cisplatin | Non-small cell lung cancer | Unknown | Sensitivity ↑ | [29] |
 | IMP3 | BCRP | Doxorubicin, Mtoxantrone | Breast cancer cell | mRNA stability ↑ | Resistance ↑ | [30] |
 | CUG-BP1 | Survivin | Camptothecin | Oesophageal cancer | mRNA stability ↑ | Resistance ↑ | [31] |
 | BRF1 | cIAP2 | Cisplatin | Head and neck squamousCarcinoma cell lines | mRNA degradation | Sensitivity ↑ | [33] |
 | HnRNPs H1/H2 | TYMP | 5′-deoxyfluorouridine | Histiocytic lymphoma cell | Splicing | Resistance ↑ | [34] |
 | MTDH | Several targets | Mitomycin C, BIBF1120 | Endometrial cancer cell line | Stress granule formation? | Resistance ↑ | [38] | </md>


[User] <|image|>Convert the photo into Markdown format.

[Assistant]
<md> |  | Average ± SD vitamin E levels (μg/mg HDL) | % change versus Hp 1-1 |
 | --- | --- | --- |
 | Hp 1-1 | 1.18 ± 0.62 | — |
 | Hp 2-1 | 0.99 ± 0.63 | −17% |
 | Hp 2-2 | 0.67 ± 0.62 | −43% | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> |  | Placebo (n = 8) | β-alanine (n = 8) |
 | --- | --- | --- |
 | Age (years) | 30.3 ± 4.5 | 28.5 ± 3.2 |
 | Height (cm) | 173 ± 0.1 | 172 ± 0.1 |
 | Weight (kg) | 79.5 ± 11.2 | 73.4 ± 12.5 |
 |

[Assistant] Body mass index (kg/m2) | 25.6 ± 1.5 | 24.6 ± 2.2 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Category | Reference level | Low exposure | Medium exposure | High exposure |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Cumulative tetrachloroethylene (for >1 μg/L –months: mean = 402.6, median = 269.5) |
 | Level* | ≤ 1 | >1 - 155 | >155 - 380 | >380 – 8,585 |
 | Number (%) | 66, 582 (43.0%) | 28,230 (18.2%) | 27,255 (17.6%) | 32,865 (21.2%) |
 | <COLSPAN=5> Cumulative trichloroethylene (for >1 μg/L –months: mean = 6,369.3, median = 5,289.0) |
 | Level* | ≤ 1 | >1 – 3,100 | >3,100 – 7,700 | >7,700 – 39,745 |
 | Number (%) | 64, 584 (41.7%) | 31,069 (20.1%) | 27,638 (17.8%) | 31,641 (20.4%) |
 | <COLSPAN=5> Cumulative vinyl chloride (for >1 μg/L –months: mean = 458.9,

[Assistant]
median = 360.6) |
 | Level* | ≤ 1 | >1 - 205 | >205 - 500 | >500 – 2,800 |
 | Number (%) | 66, 470 (42.9%) | 27,651 (17.8%) | 28,063 (18.1%) | 32,748 (21.1%) |
 | <COLSPAN=5> Cumulative benzene (for ≥2 μg/L –months: mean = 104.7, median = 83.2) |
 | Level* | < 2 | 2 - 45 | >45 - 110 | >110 - 601 |
 | Number (%) | 64, 580 (41.7%) | 24,579 (15.9%) | 31,838 (20.5%) | 33,935 (21.9%) |
 | <COLSPAN=5> Cumulative TVOC (for >1 μg/L –months: mean = 9,605.1, median = 7,652.8) |
 | Level* | ≤ 1 | >1 – 4,600 | >4,600 – 12,250 | >12,250 - 64,016 |
 | Number (%) | 57, 328 (37.0%) | 35,432 (22.9%) | 29,687 (19.2%) | 32,485 (21.0%) | </md>


[User] <|image|>Encode the picture in Markdown syntax.

[Assistant]
<md> |  | Residue | WT | R135K | Energy Difference b |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=6> NS1 | D29 | −3.25 (2.59) | −1.56 (2.39) | 1.69 |
 | Y30 | −3.02 (0.48) | −2.05 (0.77) | 0.97 |
 | K44 | 1.24 (0.65) | 1.62 (1.39) | 0.38 |
 | W72 | −6.02 (0.68) | −5.32 (0.73) | 0.70 |
 | W74 | −2.11 (0.91) | −1.52 (0.88) | 0.59 |
 | Y79 | −8.96 (0.87) | −8.04 (1.07) | 0.92 |
 | <ROWSPAN=5> H-Ras–GDP | R128 | −3.40 (2.33) | −1.15 (2.38) | 2.25 |
 | Q131 | −2.68 (1.36) | −2.01 (1.21) | 0.67 |
 | R135K | −10.56 (1.94) | −2.75 (3.27) | 7.81 |
 | I142 | −2.65 (0.76) | −2.34 (0.76) | 0.31 |
 | E143 | −1.70 (1.09) | −0.94 (1.29) | 0.76 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | Quadrant | Cases | Controls | p Value |
 | --- | --- | --- | --- |
 | Superior | 122.30±20.26 | 129.2±16.69 | 0.005 |
 | Inferior | 126.55±20.77 | 135.41±18.40 | 0.002 |
 | Nasal | 83.50±16.81 | 87.46±16.06 | 0.081 |
 | Temporal | 61.30±15.95 | 69.84±11.76 | 0.001 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Vaccination | Baseline peak time | <COLSPAN=4> Relative reduction of peak attack rate (%) | <COLSPAN=4> Relative reduction of epidemic size (%) |
 | Country |  | 15 Oc 30% cov | 15 Oct 60% cov | 15 Nov 30%

[Assistant]
cov | 15 Nov 60% cov | 15 Oct 30% cov | 15 Oct 60% cov | 15 Nov 30% cov | 15 Nov 60% cov |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | US | (23 Sep–09 Nov) | (1–15) | (1–15) | (0–2) | (0–2) | (5–25) | (5–25) | (1–2) | (1–2) |
 | UK | (10 Oct–19 Nov) | (1–29) | (1–29) | 0 | (0–1) | (11–30) | (11–31) | (1–4) | (1–4) |
 | Canada | (04 Oct–14 Nov) | (1–21) | (1–21) | (0–1) | (0–1) | (10–30) | (10–32) | (1–5) | (1–5) |
 | France | (11 Oct–21 Nov) | (2–32) | (2–32) | (0–2) | (0–2) | (12–32) | (12–33) | (1–5) | (1–5) |
 | Italy | (17 Oct–23 Nov) | (5–38) | (5–38) | (0–1) | (0–1) | (13–35) | (13–36) | (1–5) | (1–5) |
 | Spain | (09 Oct–19 Nov) | (1–30) | (1–30) | (0–1) | (0–1) | (11–32) | (11–33) | (1–4) | (1–4) |
 | Germany | (11 Oct–20 Nov) | (2–34) | (2–34) | (0–1) | (0–1) | (12–33) | (12–34) | (1–4) | (1–4) | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> |  |  | <COLSPAN=3> Is TB communicable disease? |  |  |
 | Variables | Group | Yes, 432 (51.5 %) | No, 283 (33.7 %) | No idea, 124 (14.8 %) | χ2-value | p-value |
 | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Religion | Muslim | 383 (50.9 %) | 255 (33.9 %) | 114 (15.2 %) | <ROWSPAN=2> 1.218 | <ROWSPAN=2> 0.544 |
 | Hindu | 49 (56.32 %) | 28(33.7 %) | 10(12.0 %) |
 | <ROWSPAN=2> Gender | Male | 307 (53.7 %) | 178 (31.1 %) | 87 (15.2 %) | <ROWSPAN=2> 5.52 | <ROWSPAN=2> 0.043 |
 | Female | 125 (46.8 %) | 105 (39.3 %) | 37 (13.9 %) |
 | <ROWSPAN=4> Parents’ education | No Education | 71(53.8 %) | 38(28.8 %) | 23(17.4 %) | <ROWSPAN=4> 7.25 | <ROWSPAN=4> 0.298 |
 | Primary | 69(50.4 %) | 45(32.8 %) | 23(16.8 %) |
 | Secondary | 105(52.5 %) | 61(30.5 %) | 34(17.0 %) |
 | Higher | 187(50.5 %) | 139(37.6 %) | 44(11.9 %) |
 | <ROWSPAN=2> Residence | Rural | 314(53.1 %) | 182(30.8 %) | 95(16.1 %) | <ROWSPAN=2> 8.42 | <ROWSPAN=2> 0.015 |
 | Urban | 118(47.6 %) | 101(40.7 %) | 29(11.7 %) |
 | <ROWSPAN=2> Type of family | Single Family | 349(52.2 %) | 231(34.5 %) | 89(13.3 %) | <ROWSPAN=2> 5.79 | <ROWSPAN=2> 0.045 |
 | Joint Family | 83(48.8 %) | 52(30.6 %) | 35(20.6 %) | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> |  | OR | 95% CI | p |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Mortality related risk factors |
 | Mechanical ventilation | 2.4 | 0.933–6.211 | 0.069 |
 | Use of combined antibiotics | 4.22 | 1.293–13.791 | 0.017 |
 | <COLSPAN=4> Risk factors that lengthen total stay in hospital (days) |
 | Polymicrobial bacteremia | 117.148 | 73.634–160.663 | 0.00 |
 | Prior glycopeptide use | 41.96 | 12.697–71.223 | 0.05 |
 | Presence of central venous catheter | 32.970 | 3.871–62.069 | 0.027 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | FA1090* | CREE?† | NCCP11945‡ | CREE?† |
 | --- | --- | --- | --- | --- |

[Assistant]
| previously reported: |  |  |  |  |
 | NMA2121 | not present | n/a | NGK_1900 | Yes |
 | NMB0397 | NGO1564** | no | NGK_1865/7 | Yes |
 | cvaB | unannotated†† | yes | NGK_0171 | Yes |
 | NMA0059 | unannotated | yes | NGK_2501 | Yes |
 | NMA0530 | NGO2162 | no | NGK_2641 | No |
 | new from this study: |  |  |  |  |
 |  | NGO0243 | yes | NGK_0377 | Yes |
 |  | NGO2104 | yes | NGK_2573 | Yes |
 |  | NGO1597 | yes | NGK_1901‡‡ | No | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> | Code | ART regimenb | Time on ART | PVLc |  | Mutations | Subtype |
 |  |  | (months) |  | PR | RT |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | 0053 | 1a/1c | 40 | 13945 | M36I, H69K, T74S, L89M | - | C |
 | 1959 | 1c | 26 | 598 | M36I, H69K, T74S, L89M | - | C |
 | 3438 | 1d | 13 | 495 | M36I, H69K, L89M | - | C |
 | 1739 | 1b | 25 | 18239 | M36I, H69K, L89M | K103N | C |
 | 2369 | 1c | 19 | 25678 | M36I, H69K, L89M | M41L, L210W | C | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> | Positive | Negative |
 | --- | --- |
 | “Psychiatry will become the most in demand speciality in the future”“I am interested in the conditions and I think psychiatric patients are some of the most in need yet stigmatised” | “It’s slow paced; I think you generally have to wait a long time to see improvement”“Little hand-on skills”“Higher rates of depression in psychiatrists”“Listening to someone’s problems every day and not getting affected by it would be difficult for me” | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | <ROWSPAN=2> Compound | <ROWSPAN=2> RI | Peppermint Oil | Clove oil |
 | <COLSPAN=2> Content (%) |
 | --- | --- | --- | --- |
 | α-Pinene | 934 | 0.6 | – |
 | Sabinene | 968 | 0.2 | – |
 | β-Pinene | 974 | 1.0 | – |
 | p-Cymene | 1016 | 0.3 | – |
 | 1,8-Cineole | 1020 | 6.6 | – |
 | Limonene | 1025 | 2.4 | – |
 | trans-Sabinene hydrate | 1060 | 0.2 | – |
 | 2-Methylbutyl 2-methylbutanoate | 1094 | 0.1 | – |
 | Menthone | 1138 | 23.1 | – |
 | Isomenthone | 1145 | 3.8 | – |
 | Menthofuran | 1154 | 2.2 | – |
 | Neomenthol | 1155 | 3.3 | – |

[Assistant]
| Menthol | 1163 | 43.9 | – |
 | Neoisomenthol | 1173 | 1.0 | – |
 | α-Terpineol | 1178 | 0.6 | – |
 | Isomenthol | 1179 | 0.2 | – |
 | Pulegone | 1218 | 1.2 | – |
 | Piperitone | 1237 | 0.4 | – |
 | Menthyl acetate | 1279 | 4.9 | – |
 | Eugenol | 1342 | – | 85.2 |
 | β-Burbonene | 1381 | 0.1 | – |
 | Methyleugenol | 1386 | – | 0.2 |
 | (E)-β-Caryophyllene | 1421 | 1.6 | 9.9 |
 | α-Humulene | 1453 | 0.1 | 1.9 |
 | Germacrene D | 1474 | 0.3 | – |
 | δ-Cadinene | 1513 | – | 0.4 |
 | (E)-β-Caryophyllene oxide | 1573 | 0.2 | 0.4 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Payload | CCD | IRMSS | WFI |
 | --- | --- | --- | --- |

[Assistant]
| Sensor Type | Push-broom | Electro-mechanic | Push-broom |
 | Visible and near infrared bands (μm) | 1: 0.45–0.522: 0.52–0.593: 0.63–0.694: 0.77–0.895: 0.51–0.73 | 6: 0.50–0.90 | 10: 0.63–0.6911: 0.77–0.89 |
 | Shortwave infrared bands (μm) |  | 7: 1.55–1.758: 2.08–2.35 |  |
 | Thermal infrared bands (μm) |  | 9: 10.4–12.5 |  |
 | Resolution (m) | 19.5 | Band 6–8: 78Band 9: 156 | 258 |
 | View angle | 8.32° | 8.80° | 59.6° |
 | Swath wide (km) | 113 | 119.5 | 890 | </md>


[User] <|image|>Convert the picture to Markdown syntax.

[Assistant]
<md> | Variables | N (%) | Ebp1 expression | + | ++ | +++ | p-value |
 |  |  | - |  |  |  |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> MMP9 |
 | - | 1 | 1 | 0 | 0 | 0 | <ROWSPAN=4> 0.0002 |
 | + | 1 | 0 | 0 | 1 | 0 |
 | ++ | 23 | 3 | 1 | 3 | 16 |
 | +++ | 41 | 6 | 8 | 20 | 7 |
 | <COLSPAN=7> ICAM-1 |
 | - | 50 | 8 | 8 | 16 | 18 | <ROWSPAN=4> 0.6192 |
 | + | 16 | 2 | 1 | 8 | 5 |
 | ++ | 0 | 0 | 0 | 0 | 0 |
 | +++ | 0 | 0 | 0 | 0 | 0 |
 | <COLSPAN=7> E-Cadherin |
 | - | 1 | 1 | 0 | 0 | 0 | <.0001 |
 | + | 24 | 8 | 6 | 10 | 0 |  |
 | ++ | 18 | 1 | 3 | 13 | 1 |  |
 | +++ | 22 | 0 | 0 | 1 | 21 |  | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Variable | <ROWSPAN=2> % >14 Days | <ROWSPAN=2> Crudep-Value | <COLSPAN=3> Received Mammogram Results ≤14 Days vs. >14 Days |
 | Adjusted Odds Ratio 1 | 95% CI | p-Value |
 | --- | --- | --- | --- | --- | --- |
 | Age |  | 0.65 |  |  | 0.2 |
 | <50 years (n = 239) | 18.4 | <ROWSPAN=2>  | 1.29 | <ROWSPAN=2> 0.87,1.90 | <ROWSPAN=2>  |
 | 50–79 years (n = 1403) | 19.7 | ref |
 | Residential location |  | <0.001 |  |  | <0.001 |
 | Major city (n = 910) | 11.0 | <ROWSPAN=4>  | ref |  | <ROWSPAN=4>  |
 | Inner regional (n = 380) | 20.5 | 1.71 | 1.20, 2.44 |
 | Outer regional (n = 291) | 40.6 | 4.17 | 2.95, 5.91 |
 | Remote/very remote (n = 61) | 39.3 | 3.62 | 2.00, 6.54 |
 | Area-level disadvantage |  | <0.001 |  |  | 0.07 |
 | Least disadvantaged (n = 707) | 12.3 | <ROWSPAN=3>  | ref |  | <ROWSPAN=3>  |
 | Middle socioeconomic status (n = 329) | 19.2 | 1.38 | 0.94, 2.02 |
 | Most disadvantaged (n = 606) | 28.1 | 1.45 | 1.04, 2.01 |
 | Type of screening facility |  | <0.001 |  |  | <0.001 |
 | BreastScreen (n = 1233) | 25.0 | <ROWSPAN=2>  | 9.51 | <ROWSPAN=2> 5.21, 17.36 | <ROWSPAN=2>  |
 | Private (n = 409) | 2.9 | ref |
 | Tumour size |  | 0.06 |  |  | 0.01 |
 | <1.0 cm (n = 625) | 21.1 | <ROWSPAN=4>  | ref |  | <ROWSPAN=4>  |
 | ≥1.0 cm to <2 cm (n = 694) | 18.6 | 0.66 | 0.49, 0.88 |
 | ≥2.0 cm (n = 316) | 18.0 | 0.63 | 0.44, 0.92 |
 | Missing (n = 7) | 28.6 | 3.15 | 0.41, 24.01 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Stimulant | n | Nil (Basal level) | <COLSPAN=6> fMLP |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Time |  |  | 10 s | 30 s | 60 s | Calcium ionophore | EGTA | MnCl2 |
 | Normal | 25 | 291.24 ± 53.95 | 472.15# ± 106.93 | 466.93# ± 158.45 | 339.34# ± 69.58 | 728.07# ± 155.05 | 601.76# ± 155.55 | 193.14$ ± 39.20 |
 | CML | 27 | 236.69 ± 22.33 | 412.31# ± 106.52 | 384.76# ± 88.21 | 248.15# ±64.75 | 610.28# ± 158.6 | 601.84# ± 164.83 | 240.32# ± 75.77 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Electrical variable | Frequency (Hz) | Sensitivity score | r2 |
 | --- | --- | --- | --- |
 | Cp | 116 | 0.49 | 0.542 |
 |  | 1250 | 0.46 | 0.524 |
 |  | 13,458 | 0.50 | 0.605 |
 | Cs | 116 | 0.10 | 0.119 |
 |  | 1250 | 0.29 | 0.331 |
 |  | 13,458 | 0.38 | 0.436 |
 | Rp | 116 | 0.40 | 0.584** |
 |  | 1250 | 0.45 | 0.635** |
 |  | 13,458 | 0.38 | 0.599** |
 | Rs | 116 | 0.39 | 0.563** |
 |  | 1250 | 0.44 | 0.615** |
 |  | 13,458 | 0.44 | 0.639** |
 | G | 116 | 0.28 | 0.317 |
 |  | 1250 | 0.35 | 0.394 |
 |  | 13,458 | 0.45 | 0.502 |
 | Z | 116 | 0.39 | 0.574** |
 |  | 1250 | 0.44 | 0.628** |
 |  | 13,458 | 0.41 | 0.622** |
 | X | 116 | 0.18 | 0.281 |
 |  | 1250 |

[Assistant]
0.42 | 0.595** |
 |  | 13,458 | 0.46 | 0.650** |
 | Θ | 116 | 0.00 | 0.197 |
 |  | 1250 | 0.00 | 0.214 |
 |  | 13,458 | 0.03 | 0.267 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Covariate | <COLSPAN=4> Case group (N = 209) | <COLSPAN=4> Control group (N = 488) |
 |  | % | N | Mean | SD | % | N | Mean | SD |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Sex = male | 45.0 | 94 |  |  | 47.8 | 233 |  |  |
 | Smoking | 35.9 | 75 |  |  | 21.7 | 106 |  |  |
 | Q1 |  |  | 0.91 | 0.80 |  |  | −0.39 | 0.81 |
 | Q2 |  |  | 0.59 | 0.99 |

[Assistant]
|  | −0.25 | 0.89 |
 | Q4 |  |  | −0.80 | 0.99 |  |  | 0.34 | 0.78 | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | <COLSPAN=2> Classifier | <COLSPAN=4> SVM | <COLSPAN=4> RF |
 | <COLSPAN=2> Features selection | None | SURF [28] | Fisher | RF Gini | None | SURF [28] | Fisher | RF Gini |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 12_3_4 | Acc. | 0.466 | 0.464 | 0.529 | 0.557 | 0.607 | 0.493 | 0.571 | 0.586 |
 | 1_23_4 | Acc. | 0.550 | 0.550 | 0.550 | 0.550 | 0.643 | 0.329 | 0.557 | 0.693 |
 | 1_2_3_4 | Acc. | 0.207 | 0.300 | 0.450 | 0.507 | 0.486 | 0.350 | 0.393 | 0.521 | </md>


[User] <|image|>Encode the picture in Markdown syntax.

[Assistant]
<md> |  | Bound | Unbound | Model |
 | --- | --- | --- | --- |
 | R1 | 1.9 | 4.9 | 2.0 |
 | R2 | 3.0 | 4.2 | 1.3 |
 | R3 | 2.5 | 3.7 | 1.4 |
 | R4 | 2.4 | 3.7 | 2.1 |
 | R5 | 2.1 | 3.2 | 1.8 |
 | R6 | 1.6 | 3.8 | 1.5 |
 | R7 | 1.0 | 3.9 | 1.8 |
 | R8 | 2.6 | 3.6 | 2.6 |
 | R9 | 2.4 | 3.7 | 1.2 |
 | R10 | 2.1 | 4.1 | 1.6 |
 | PIGS | 5.8 | 6.9 | 6.8 |
 | Bound | 2.0 | 1.9 | 1.1 | </md>


[User] <|image|>Interpret the picture as Markdown format.

[Assistant]
<md> | S/no. | Variable | Frequency (n) | Percentage (%) |
 | --- | --- | --- | --- |
 | 1. | <COLSPAN=3> Age |
 |  | 14–19 | 104 | 26.8 |
 |  | 20–24 | 214 | 55.2 |
 |  | 25+ | 70 | 18.0 |
 | 2. | <COLSPAN=3> Marital status |
 |  | Never married | 360 | 92.8 |
 |  | Ever married/cohabiting | 28 | 7.2 |
 | 3. | <COLSPAN=3> Religion |
 |  | Christianity | 283 | 72.9 |
 |  | Islam | 105 | 27.1 |
 | 4. | <COLSPAN=3> Ethnicity |
 |  | Yoruba | 332 | 85.6 |
 |  | Others | 56 | 14.4 |
 | 5. | <COLSPAN=3> Type of institution |
 |  | Polytechnic student | 159 | 41.0 |
 |  | University student | 138 | 35.6 |
 |  | College of education student | 91 | 23.5 |
 | 6. | <COLSPAN=3> Level of education |
 |  | 1st year | 80 | 20.6 |
 |  | 2nd year | 143 | 36.9 |
 |  | 3rd year | 99 | 25.5 |
 |  | 4th year and above | 66 | 17.0 |
 | 7. | <COLSPAN=3> Family setting |
 |  | Monogamous | 280 | 72.2 |
 |  | Polygamous | 108 | 27.8 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  | HBV DNA+ | HBV DNA- |  | Sensitivity(%) | Specificity(%) | PPV(%) | NPV (%) | Overall (%) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | HBpreSAg+ | 48 | 34 |  | 68 | 56 | 59 | 66 | 62 |
 | HBpreSAg- | 23 | 44 | CI,95% | 55–78 | 45–67 |  |  |  |
 | <COLSPAN=2> n = 149 | <COLSPAN=7>  |
 |  | HBV DNA+ | HBV DNA- |  | Sensitivity(%) | Specificity(%) | PPV(%) | NPV (%) | Overall (%) |

[Assistant]
 | HBeAg+ | 43 | 7 |  | 61 | 91 | 86 | 72 | 77 |
 | HBeAg- | 28 | 71 | CI,95% | 48–72 | 82-96 |  |  |  |
 | <COLSPAN=2> n=149 | <COLSPAN=7>  |
 |  | HBeAg+ | HBeAg- |  | Sensitivity(%) | Specificity(%) | PPV(%) | NPV (%) | Overall (%) |
 | HBpreSAg+ | 35 | 49 |  | 70 | 53 | 42 | 79 | 58 |
 | HBpreSAg- | 15 | 55 | CI,95% | 55-82 | 43-63 |  |  |  |
 | <COLSPAN=2> n=154 | <COLSPAN=7>  | </md>


[User] <|image|>Encode the image in Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2> Access and adherence to ART | Total (n = 328) | Male (n = 169) | Female (n = 159) | <ROWSPAN=2> p-value* |
 | n (%) | n (%) | n (%) |
 | --- | --- | --- | --- | --- |
 | Mean number of days the drug supply is usually given | 58.4 ± 53.9 | 61.4 ± 73.7 | 55.1 ± 14.9 | 0.3 |
 | <COLSPAN=4> Ever shared your drugs to other persons | – |
 | No | 328 (100) | 169 (100) | 159 (100) |  |
 | Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 | <COLSPAN=4> Having been asked to come back earlier than appointment | 0.56 |
 | No | 283 (86.3) | 144 (85.2) | 139 (87.4) |  |
 | Yes | 45 (13.7) | 25 (14.8) | 20 (12.6) |  |
 | <COLSPAN=4> Reasons for coming back earlier than appointment | 0.35 |
 | Lack of medicines | 10 (22.2) | 5 (20.0) | 5 (25.0) |  |
 | Additional check up | 21 (46.7) | 10 (40.0) | 11 (55.0) |  |
 | Other | 14 (31.1) | 10 (40.0) | 4 (20.0) |  |
 | <COLSPAN=4> Having been asked to buy any other medicines | 0.81 |
 | No | 319 (97.3) | 164 (97.0) | 155 (97.5) |  |
 | Yes | 9 (2.7) | 5 (3.0) | 4 (2.5) |  | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  | <COLSPAN=2> Average sample (design effect ratio = 1.19) | <COLSPAN=2> High psychological distress (design effect ratio = 1.32) |
 |  | LA-RDD n = 2,000 | EWP n = 2,380 | LA-RDD n = 1,960 | EWP n = 2,600 |
 | Number of dialling | 29,800 | 23,562 | 29,204 | 25,740 |
 | Costed dialling * | 16,600 | 15,708 | 16,268 | 17,160 |
 | Calling time (in hours) | 1,180 | 1,249.5 | 1,156.4 | 1,365 |
 | --- | ---

[Assistant]
| --- | --- | --- |
 | Cost† | $26,920 | $28,132 | $26,382 | $30,732 | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | <ROWSPAN=3> Year | <COLSPAN=5> No. of samples (%) |
 | <ROWSPAN=2> Recombinant | Belem

[Assistant]
| <COLSPAN=2> Sal-1 | <ROWSPAN=2> Total |
 | B-1 | S-a | S-b |
 | --- | --- | --- | --- | --- | --- |
 | 2011 | 24 (28.2) | 16 (18.9) | 24 (28.2) | 21 (24.7) | 85 |
 | 2012 | 92 (37.1) | 50 (20.2) | 60 (24.2) | 46 (18.5) | 248 |
 | 2013 | 48 (36.4) | 32 (24.2) | 32 (24.2) | 20 (15.2) | 132 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | Haplotypea | <COLSPAN=2> Estimated frequency |
 | --- | --- | --- |
 |  | Severe malaria | Mild malaria |

[Assistant]
| 1: CCTGGGCATCAACTCT | 0.095 | 0.163 |
 | 2: TATACCAGATGATCAC | 0.723 | 0.637 |
 | 3: CAGACCAGATGATCAC | 0.03 | 0.018 |
 | 4: TATACCAGATGATCCC | 0.025 | 0.04 |
 | 5: CATACCAGATGATCAC | 0.057 | 0.045 |
 | 6: CAGACCAGATGCTCAC | 0.038 | 0.048 | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Country and program stage | Sample size, n | Message coverage2 | Contact coverage3 | Effective coverage4 |
 | --- | --- | --- | --- | --- |
 | Bangladesh5 |  |  |  |  |
 | Survey 1.1A | 1927 | 44.7 (41.3, 48.4) | 23.5 (20.8, 26.7) | 2.1 (1.4, 3.2) |
 | Survey 1.2A | 1924 | 63.7 (60.0, 67.1) | 36.8 (33.4, 40.9) | 3.9 (2.7, 5.5) |
 | Survey 2 | 2887 | 46.3 (43.3, 49.4) | 26.3 (23.6, 28.6) | 0.8 (0.4, 1.2) |
 | Côte d’Ivoire |  |  |  |  |
 | End-line | 776 | 85.0 (82.3, 87.3) | 37.5 (32.8, 42.5) | 4.6 (2.9, 7.2) |
 | Ghana6 |  |  |  |  |
 | Survey 1.1B | 306 | 97.7 (92.9, 100.0) | 94.4 (89.7, 98.1) | 88.3 (81.1, 94.6) |
 | Survey 1.2B | 306 | 99.0 (91.8, 100.0) | 92.0 (82.7, 98.7) | 83.1 (73.4, 93.1) |
 | Survey 1.3 | 307 | 99.7 (98.4, 100.0) | 84.4 (77.6, 89.9) | 61.9 (53.2, 69.9) |
 | Survey 2.1 | 620 | 63.8 (57.2, 71.1) | 23.5 (19.0, 28.5) | 15.3 (11.3, 19.8) |
 | Survey 2.2 | 663 | 89.8 (86.6, 92.4) | 52.8 (47.7, 58.9) | 9.4 (6.7, 12.4) |
 | India |  |  |  |  |
 | End-line | 905 | 93.7 (82.4, 97.9) | 86.8 (73.1, 94.1) | 57.2 (48.2, 65.8) |
 | Vietnam |  |  |  |  |
 | End-line | 962 | 29.0 (21.9, 35.9) | 22.6 (17.4, 28.2) | 12.5 (8.3, 16.8) | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Database | Sample count | Gene count | Database url | Reference |
 | --- | --- | --- | --- | --- |
 | ProteomicsDB | 577 | 17,153 | https://www.proteomicsdb.org/ | (5)

[Assistant]
|
 | MOPED | 172 | 17,164 | http://moped.proteinspire.org | (8) |
 | PaxDB | 11 | 19,851 | http://pax-db.org/#!home | (9) |
 | MaxQB | 11 | 10,059 | http://maxqb.biochem.mpg.de/mxdb/ | (10) | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> |  | n | Age (years) | Weight (kg) | Height (cm) |
 | --- | --- | --- | --- | --- |
 | Males | 308 | 73.5 ± 5.7 (65–91) | 84.3 ± 14.0 (56–125) | 174.3 ± 7.2

[Assistant]
(147–198) |
 | Females | 125 | 76.8 ± 7.4 (53–98) | 66.4 ± 11.1 (40–96) | 158.1 ± 6.7 (141–175) | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> |  | Site | Sex | Implant observed | Bone resorption (mm) (mean ± SD) | t test P value |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=4> Sur-6 months | <ROWSPAN=2> Mesial | Male | 20 | 0.56 ± 0.86 | <ROWSPAN=2> .809 |
 | Female | 12 | 0.63 ± 0.65 |
 | <ROWSPAN=2> Distal | Male | 20 | 0.23 ± 0.21 | <ROWSPAN=2> .002 |
 | Female | 12 | 0.84 ± 0.53 |
 | <ROWSPAN=4> Prosthesis | <ROWSPAN=2> Mesial | Male | 20 | 0.77 ± 1.33 | <ROWSPAN=2> .021 |
 | Female | 12 | 1.90 ± 1.19 |
 | <ROWSPAN=2> Distal | Male | 20 | 0.48 ± 0.49 | <ROWSPAN=2> .003 |
 | Female | 12 | 1.67 ± 1.06 |
 | <ROWSPAN=4> Total | <ROWSPAN=2> Mesial | Male | 20 | 1.33 ± 1.81 | <ROWSPAN=2> .064 |
 | Female | 12 | 2.54 ± 1.55 |
 | <ROWSPAN=2> Distal | Male | 20 | 0.71 ± 0.52 | <ROWSPAN=2> .001 |
 | Female | 12 | 2.51 ± 1.41 | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> | Event | Time | Minutes | EtCO2 | RR | BP | Pulse | O2 saturation |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Initial patient presentation to ED | 11/29/16 16:59:00 | 0 | <ROWSPAN=2> NA | 24 | 119/73 | 144 | 97% (room air) |
 | 11/29/201619:15 | 16 | 21 | 128/50 | 133 | 99% (room air) |
 | C-section procedure start | 11/29/16 19:55:00 | 56 | 32 | ETT | 128/75 | 120 | 96% (on ETT) |
 | Delivery of baby | 11/29/16 19:56:00 | 57 | 0 | ETT | 72/48 | 140 | 72% (on ETT) |
 | A-OK therapy initiated

[Assistant]
| 11/29/16 19:57:00 | 58 |  | ETT | 80/50 | 130 | 94% (on ETT) |
 | (Effect of) A-OK therapy | 11/29/16 20:00:00 | 61 | 35 | ETT | 138/68 | 140 | 97% (on ETT) |
 | Operating room timeout | 11/29/16 21:20:00 | 81 | 37 | 21 | 140/94 | 140 | 94% (on ventilator) | </md>


[User] <|image|>Convert the photo into Markdown format.

[Assistant]
<md> |  | AICA sensitivity (%) | PICA sensitivity (%) |
 | --- | --- | --- |
 | Direction-changing nystagmus | 60 | 56.3 |
 | Skew | 60 | 53.1 |
 | HIT | 30 | 100 |
 | Grade ataxia 1 | 0 | 9.4 |
 | Ataxia 2 | 20 | 28.1 |
 | Ataxia 3 | 80 | 62.5 |
 | Ataxia 2–3 | 100 | 90.6 |
 | Asynergy | 100 | 90.6 |
 | HINTS | 100 | 100 |
 | Ataxia 2–3 + nystagmus | 100 | 100 |
 | Ataxia 2–3 + skew | 100 | 100 |
 | Ataxia 2–3 + HIT | 100 | 100 | </md>


[User] <|image|>Translate the photo into Markdown format.

[Assistant]
<md> | Items | Basal diet (B) | Chicory forage (C) | Ribwort forage (R) |
 | --- | --- | --- | --- |
 | Ash | 67.0 | 255.6 | 133.6 |
 | Crude protein | 211.4 | 195.2 | 169.4 |
 | Crude fat | 26.9 | 15.6 | 11.1 |
 | Starch | 463.0 | 24.5 | 9.5 |
 | WSC | 60.5 | 11.5 | 42.0 |
 | NDF | 107.6 | 268.0 | 352.0 |
 | NSP |  |  |  |
 | Total | 187.2 | 311.0 | 308.5 |
 | Insoluble | 142.6 | 194.9 | 229.5 |
 | Glucose |  |  |  |
 | Total | 89.4 | 133.7 | 134.9 |
 | Insoluble | 56.9 | 118.3 | 134.9 |
 | Arabinose |  |  |  |
 | Total | 25.0 | 13.4 | 17.8 |
 | Insoluble | 22.4 | 5.6 | 10.4 |
 | Xylose |  |  |  |
 | Total | 56.7 | 31.1 | 32.1 |
 | Insoluble | 56.2 | 27.2 | 26.8 |
 | Uronic acid |  |  |  |
 | Total | 7.4 | 97.0 | 88.3 |
 | Insoluble | 4.0 | 21.2 | 19.9 |
 | Klason Lignin | 34.9 | 107.2 | 77.7 |
 | Dietary fibre | 222.0 | 418.4 | 386.2 | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | KEGG name | Modules |
 | --- | --- |
 | ABC transporters | 5 |
 | Flagellar assembly | 1 |
 | Porphyrin and chlorophyll metabolism | 1 |
 | Oxidative phosphorylation | 1 |
 | Bacterial secretion system | 2 |
 | Two-component system | 2 |
 | Phenylalanine, tyrosine and tryptophan biosynthesis | 1 |
 | Phenylalanine metabolism | 1 |
 | Starch and sucrose metabolism | 1 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Populations compareda | Snnb | HSTc |
 | --- | --- | --- |
 | <COLSPAN=3> By geographic region |
 | Region A (36) vs. region B (14) vs. region C (10) vs. region D (6) | 0.5468* | 0.0469** |
 | <COLSPAN=3> By host origin |
 | triticale (33) vs. wheat (33) | 0.8654** | 0.0397** |
 | <COLSPAN=3> By year of collection within host origin wheat |
 | Region D 1980’s (6) vs. Region A-B-C 2009–2010 | 0.7283ns | −0.0025ns |
 | <COLSPAN=3> By geographic region within host origin triticale |
 | region A (16) vs. region B (8) vs. region C (9) | 0.5899** | 0.1008** |
 | region A (16) vs. region B (8) | 0.6597ns | 0.0019ns |
 | region A (16) vs. region C (9) | 0.7667* | 0.1116* |
 | region

[Assistant]
B (8) vs. region C (9) | 0.8677* | 0.1428* |
 | <COLSPAN=3> By pathogenicity |
 | Pathogenic (37) vs. non-pathogenic (29) on triticale | 0.9811** | 0.0565** | </md>


[User] <|image|>Translate the photo into Markdown format.

[Assistant]
<md> |  | I. ricinus | I. persulcatus | TOTAL |
 |  | No. of ticks positive/total positive (prevalence, %) | No. of ticks positive/total positive (prevalence, %) | No. of ticks positive/total positive (prevalence, %) |
 | --- | --- | --- | --- |
 | B. afzelii VS461 | 60/187 (32.1%) | 32/88 (36.4%) | 92/275 (33.5%) |
 | B. afzelii NT28 | 37/187 (18.8%) | 5/88 (5.7%) | 42/275 (15.3%) |
 | VS461+ NT28 | 8/187 (4.3%) | 5/88 (5.7%) | 13/275 (4.7%) |
 | Total B. afzelii | 105/ 187 (56.1%) | 42/ 88 (47.7%) | 147/ 275 (53.5%) |
 | B. garinii 20047 | 38/187 (20.3%) | 9/88 (10.2%) | 47/275 (17.1%) |
 | B. garinii NT29 | 0/187 | 25/88 (28.4%) | 25/275 (9.1%) |
 | Total B. garinii | 38/ 187(20.3%) | 34/ 88 (38.6%) | 72/ 275 (26.2%) |
 | B. valaisiana | 13/ 187 (6.9%) | 2/ 88 (2.3%) | 15/ 275 (5.5%) |
 | B. burgdorferi s.s. | 3/ 187 (1.6%) | 0/ 88 | 3/ 275 (1.1%) |
 | B. bavariensis | 1/ 187 (0.5%) | 0/ 88 | 1/275 (0.4%) |
 | Mix of several genotypes | 27/ 187 (14.4%) | 10/ 88 (11.4%) | 37/275 (13.5%) | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> | <COLSPAN=2> Multivariate analysis |
 | Variable | P-value (overall survival) |
 | --- | --- |
 | AJCC staging | <0.0001* |
 | age (20 < vs ≥20) | 0.2819 |
 | Sex | 0.5497 |
 | FOXM1 | 0.0302* | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> |  | No. of hypertensives | Mean blood pressure mmHg (SD) | %ACE/ARB | %CCB | %Thiazides | %Beta-blockers | %Alpha blockers | Mean no.of drugs |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | eGFR > 60 ml/min/1.73 m2 |  |  |  |  |  |  |  |  |
 | White | 10 546 | 136.5 (15.5) | 54.3 | 48.1 | 41.9 | 27.1 | 9.8 | 1.81 |
 | South Asian | 4 557 | 132.4 (16.1) | 51.5 | 47.1 | 32.5 | 25.5 | 7.6 | 1.64 |
 | Black | 5 508 | 138.2 (16.1) | 43.2 | 71.4 | 53.0 | 22.0 | 14.7 | 2.04 |
 | ANOVA p value |  | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 |
 | eGFR < 60 ml/min/1.73 m2 |  |  |  |  |  |  |  |  |
 | White | 3 407 | 136.1 (17.4) | 64.2 | 56.3 | 35.7 | 16.2 | 43.5 | 2.16 |
 | South Asian | 767 | 134.3 (18.8) | 60.3 | 56.7 | 32.7 | 12.4 | 37.4 | 2.00 |
 | Black

[Assistant]
| 1 223 | 138.9 (18.4) | 58.5 | 72.9 | 30.3 | 22.7 | 53.7 | 2.38 |
 | ANOVA p value |  | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.01 | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Subject |
 |  | Male | Female |
 | --- | --- | --- |
 | Age | 27 | 25 |
 | Height | 167 cm | 151 cm |
 | Weight | 64 Kg | 52 Kg |
 | Head circumference | 56.5 cm | 55.5 cm |
 | Neck circumference | 32 cm | 30 cm | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Noise duration | trial 1 | trial 2 | trial 3 | average |
 | --- | --- | ---

[Assistant]
| --- | --- |
 | 0.1 s | 0.92 | 0.92 | 0.90 | 0.91 |
 | 0.2 s | 0.90 | 0.89 | 0.92 | 0.90 |
 | 0.3 s | 0.91 | 0.90 | 0.89 | 0.90 | </md>


[User] <|image|>Encode the picture in Markdown syntax.

[Assistant]
<md> | Flies bearing transgene h14-3-3γ * | Heat-shock induction of transgene | Numbers of cells in "S" phase | Numbers of eye imaginal discs observed |
 | --- | --- | --- | --- |
 | None (Control) |  |  |  |
 | - HS | NO | 4.14 (± 1.03) | 8 |
 | + HS | NO | 8.29 (± 3.11) | 8 |
 | h14-3-3γ |  |  |  |
 | - HS | NO | 9.90 (± 1.92) | 11 |
 | + HS | YES | 11.0 (± 5.69) | 3 |
 | Both HS1433GA & HS1433GC |  |  |  |
 | - HS | NO | 8.0 (± 1.91) | 10 |
 | + HS | YES | 20.5 (± 2.32)a | 11 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Characteristics | p-value* |
 | --- | --- |
 | <COLSPAN=2> Anatomical success at 6 months vs |
 | CD4 counts at RD | 0.915 |
 | CMVR activity at surgery | 0.570 |
 | CMV size </> 50% | 0.197 |
 | Macula on/off RD | > 0.999 |
 | Presence of PVR | 0.272 |
 | Presence of IRU | 0.603 |
 | Concurrent scleral buckling | 0.628 |
 | 23G/20G vitrectomy | 0.201 |
 | <COLSPAN=2> Functional success at 6 months vs |
 | CD4 counts at RD | 0.847 |
 | CMV size </> 50% | 0.103 |

[Assistant]
 | CMVR activity at surgery | 0.314 |
 | CMV macula involvement | 0.088 |
 | RD size </> 50% | 0.321 |
 | Macula on/off RD | > 0.999 |
 | Presence of PVR | > 0.999 |
 | Presence of IRU | 0.367 |
 | 23G/20G vitrectomy | 0.090 | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> | Canonical Pathways | p-value |
 | --- | --- |
 | <COLSPAN=2> Green Module |
 | IL-10 Signaling | 4.47E-08 |
 | TREM1 Signaling | 1.14E-06 |
 | PPAR/RXR Activation | 3.96E-06 |
 | Fc Receptor-mediated Phagocytosis in Macrophages and Monocytes | 9.75E-06 |
 | PPAR Signaling | 9.75E-06 |
 | <COLSPAN=2> Yellow Module |
 | IL-8 Signaling | 5.90E-09 |
 | Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | 8.84E-07 |
 | Caveolar-mediated Endocytosis Signaling | 2.29E-05 |
 | Role of Tissue Factor in Cancer | 2.95E-05 |
 | Relaxin Signaling | 3.26E-05 |
 | <COLSPAN=2> Brown Module |
 | tRNA Charging | 2.06E-10 |
 | Purine Nucleotides De Novo Biosynthesis II | 5.12E-04 |
 | Cleavage and Polyadenylation of Pre-mRNA | 8.27E-04 |
 | Nur77 Signaling in T Lymphocytes | 1.61E-03 |
 | Leucine Degradation I | 2.17E-03 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> |  | Standard 2D FLASH | CAIPIRINHA 3D FLASH | T1w TSE triggered | T2w TIRM | T2w HASTE FS |
 | --- | --- | --- | --- | --- | --- |
 | TR, ms | 86.0 | 6.1 | 2000 | 8290 | 1000 |
 | TE, ms | 3.8 | 3.0 | 2.5 | 84 | 102 |
 | Flip angle, ° | 90

[Assistant]
| 10 | 15 | 180 | 160 |
 | Scan orientation | Transverse | Transverse | Transverse | Coronal | Coronal |
 | In-plane resolution, mm | 1.3 × 1.3 | 1.0 × 1.0 | 0.7 × 0.7 | 0.8 × 0.8 | 1.0 × 1.0 |
 | Slice thickness, mm | 5 | 3–5 | 4 | 4 | 4 |
 | FOV, mm | 250 | 250 | 350 | 350 | 350 |
 | iPAT | None | Acceleration factor = 4 | None | Acceleration factor = 2 | Acceleration factor = 2 |
 | Breath-hold | 22 s | 15 s | Respiratory-triggered | 20 s | 21 s |
 | Scan time | 4 min 3 s | 15 s | 6 min 10 s | 3 min 5 s | 42 s | </md>


[User] <|image|>Interpret the table as Markdown format.

[Assistant]
<md> |  |  | <COLSPAN=2> Nuclear c-Myc expression |  |
 |  | N | Positive | Negative | P value |
 | --- | --- | --- | --- | --- |
 | Ovarian cancer | 138 | 40 | 98 |  |
 | Ovarian tissues | 47 | 6 | 41 | 0.031 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Allergen | <COLSPAN=2> Concentration of the allergen |
 | --- | --- | --- |
 |  | SPT | BAT |
 | Cat pelt | 10,000 BAU/ml | 100 BAU/ml |
 | Dog epithelium | 1:20 | 1:2000 |
 | Dermatophagoides pteronyssius (DP) | 1000 AU/ml | 100 AU/ml |
 | Dermatophagoides farinae (DF) | 1000 AU/ml | 100 AU/ml |
 | Alternaria | 1:10 | 1:1000 |
 | Hormodendrum/Cladosporium | 1:10 | 1:1000 |
 | Timothy grass pollen | 100,000 AU/ml | 1000 AU/ml [BAT] |
 | Short ragweed pollen | 1:20 | 1:2000 |
 | Birch tree (Betula verrucosa) pollen | 1:20 | 1:2000 | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Hybrid Capture-II (HC-II) | <COLSPAN=2> HPV-16 E6 PCR | Total |
 |  | HPV-16 E6 Positive | HPV-16 E6 Negative |  |
 | --- | --- | --- | --- |
 | HC-II Positive | 42 (77.78%) | 15 (9.74%) | 57 (100) |
 | HC-II Negative | 12 (22.22%) | 139 (90.26%) | 151 (100) |
 | Total | 54 | 154 | 208 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | Characteristic | Refugee n | Refugee mean (95% CI) | Cameroonian n | Cameroonian mean (95% CI) |
 | --- | --- | --- | --- | --- |
 | Average daily income, CFA | 188 | 842.38 (593.58 – 1091.18) | 394 | 1172.53 (1001.66 – 1343.39) |
 | Average size of land owned, hectares | 187 | 1.54 (0.38 – 2.69) | 397 | 1.26 (0.68 – 1.83) |
 | Cows owned by household | 191 | 6.6 (0.2 – 12.9) | 396 | 6.2 (3.9 –

[Assistant]
8.5) |
 | Chickens owned by household | 191 | 2.3 (1.5 - 3.2) | 396 | 2.3 (1.6 – 3.0) |
 | Day without food in the past month | 191 | 1.7 (1.6 – 1.8) | 395 | 1.7 (1.7 – 1.8) | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> |  | Prenotification (n = 727) | No prenotification (n = 201) | p-value |
 | --- | ---

[Assistant]
| --- | --- |
 | Total prehospital time, median | 22.5 (18.5–26.0) | 22 (17.5–26.5) | 0.433 |
 | Door to CT time, median | 13 (10.0–18.0) | 19 (13.0–34.0) | <0.001 |
 | Door to CT time ≤ 25 min | 660 (90.8 %) | 125 (62.2 %) | <0.001 |
 | Door to needle time, median | 63 (49.0–79.0) | 68 (54.0–86.0) | 0.138 |
 | Door to needle time ≤ 60 min | 65 (45.1 %) | 7 (28.0 %) | 0.110 |
 | Administering thrombolytic therapy | 144 (19.8 %) | 25 (12.4 %) | 0.017 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | Characteristics | Outpatient(n=55) | Hospitalized(n=344) | P value |
 | --- | --- | --- | --- |
 | RSV A | 42 (76.4%) | 242 (70.3%) | 0.36 |
 | RSV B | 12 (21.8%) | 98 (28.5%) | 0.31 |
 | RSV A and B coinfection | 1 (1.8%) | 4 (1.2%) | >0.99 |
 | Other respiratory pathogen | 23 (41.8%) | 74 (21.5%) | 0.001 |
 | Age (years) (mean, SD) | 2.4 (3.2) | 1.3 (2.1) | 0.018 |
 | <COLSPAN=4> Gender |
 | Male | 29 (52.7%) | 204 (59.3%) | 0.36 |
 | Female | 26 (47.3%) | 140 (40.7%) |  |
 | <COLSPAN=4> Smoking history |
 | Never smoked | 45 (81.8%) | 277 (80.5%) | 0.82 |
 | Former/current/passive smoker | 10 (18.2%) | 67 (19.5%) |  |
 | <COLSPAN=4> Underlying conditions |
 | Any underlying condition | 14 (25.4%) | 142 (41.3%) | 0.026 |
 | Cardiovascular disorder | 0 | 8 (2.3%) | 0.61 |
 | Activities of daily living impaired | 0 | 2 (0.6%) | 1 |
 | Hematological malignancy | 0 | 3 (0.9%) | 1 |
 | Chronic lung disease | 2 (3.6%) | 12 (3.5%) | 1 |
 | Solid organ malignancy | 0 | 1 (0.3%) | 1 |
 | Neuromyopathy | 0 | 1 (0.3%) | 1 |
 | Immunodeficiencies | 1 (1.8%) | 4 (1.2%) | 0.53 |
 | Congenital malformations/congenital syndromes | 4 (7.3%) | 68 (19.8%) | 0.023 |
 | Renal disorder | 0 | 1 (0.3%) | 1 |
 | Asthma | 2 (3.6%) | 14 (4.1%) | 1 |
 | Cognitive dysfunction | 2 (3.6%) | 9 (2.6%) | 0.65 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  | Site 1 | Site 2 | Site 3 | Site 4 | All sites |
 | --- | --- | --- | --- | --- | --- |
 | Latitude | 17.284 | 17.283 | 17.282 | 17.278 | - |
 | Longitude | −87.808 | −87.814 | −87.815 | −87.815 | - |
 | N | 8 | 57 | 18 | 35 | 118 |
 | <COLSPAN=6> Genetic diversity |
 | Ar | 3.84 | 4.73 | 4.23 | 4.31 | 4.28 |
 | FIS | 0.83 | 0.55 | 0.76 | 0.60 | 0.63 |
 | HL | 0.86 | 0.68 | 0.87 |

[Assistant]
0.73 | 0.77 |
 | SR | 0.72 | 0.62 | 0.51 | 0.66 | 0.63 |
 | SI | 0.76 | 0.62 | 0.68 | 0.69 | 0.69 |
 | J′ | 0.33 | 0.46 | 0.25 | 0.42 | 0.41 |
 | R | 0.018 | −0.001 | 0.013 | 0.007 | 0.000 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Under-sampling | <COLSPAN=2> SVM | <COLSPAN=2> MyC | <COLSPAN=2> RIPPER | <COLSPAN=2> C4.5 | Imbalance |
 | (%) | Sens. | Spec. | Sens. | Spec. | Sens. | Spec. | Sens. | Spec. | ratio |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 0 | 0.89 | 0.77 | 0.92 | 0.68 | 0.91 | 0.71 | 0.90 | 0.79 | 42 |
 | 10 | 0.89 | 0.76 | 0.93 | 0.65 | 0.91 | 0.75 | 0.90 | 0.80 | 38 |
 | 20 | 0.89 | 0.75 | 0.93 | 0.63 | 0.91 | 0.73 | 0.91 | 0.79 | 34 |
 | 30 | 0.89 | 0.76 | 0.94 | 0.61 | 0.93 | 0.72 | 0.90 | 0.78 | 30 |
 | 40 | 0.89 | 0.73 | 0.93 | 0.60 | 0.92 | 0.69 | 0.91 | 0.77 | 25 |
 | 50 | 0.90 | 0.70 | 0.93 | 0.58 | 0.92 | 0.71 | 0.91 | 0.76 | 21 |
 | 60 | 0.90 | 0.71 | 0.94 | 0.56 | 0.92 | 0.72 | 0.92 | 0.73 | 17 |
 | 70 | 0.91 | 0.67 | 0.95 | 0.55 | 0.91 | 0.72 | 0.92 | 0.70 | 13 |
 | 80 | 0.92 | 0.64 | 0.94 | 0.49 | 0.92 | 0.73 | 0.92 | 0.68 | 9 |
 | 90 | 0.94 | 0.52 | 0.91 | 0.60 | 0.93 | 0.67 | 0.93 | 0.59 | 5 |
 | 100 | 0.99 | 0.12 | 0.99 | 0.07 | 0.99 | 0.03 | 0.99 | 0.14 | 0.5 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> |  | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
 | --- | --- | --- | --- | --- | --- |
 | Number of NGS runs | 1 | 1 | 1 | 2 | 2 |
 | 454 experiment | Standard 1/3 run | Standard 1/3 run | Standard 1/3 run | Standard 1/5 Titanium 1/12 | Standard 1/5 Titanium 1/12 |
 | Mapped reads | 127980 | 96538 | 111492 | 24940* (Std) 24192* (Tit) | 16767* (Std) 40169* (Tit) |
 | Total average coverage | 221 | 168 | 194 | 73* | 88* |
 | % sequenced amplicons with coverage > 38 | 94.4 | 93.2 | 96.3 | 80.3 | 85.3 |
 | % sequenced amplicons with coverage > 30 | 95.3 | 94.6 | 97.2 | 86.8 | 91.5 |
 | % sequenced amplicons with coverage > 5 | 97.2 | 97.2 | 99.0 | 94.6 | 96.3 |

[Assistant] | Mutations | New mutation found in CDH23 | New mutation found in CDH23 | No mutation could be clearly identified | New mutation found in OTOF | Known mutation in TMC1 confirmed | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | <ROWSPAN=2> Secondary structures | <ROWSPAN=2> Wavenumber (cm-1) | <COLSPAN=4> L-cysteine (g/l) |
 | 0.0 | 0.5 | 1.0 | 1.5

[Assistant]
|
 | --- | --- | --- | --- | --- | --- |
 | Aggregated strands (%) | 1625-1610 | 1.55 | 1.21 | 2.51 | 2.01 |
 | β-Sheet (%) | 1640-1630 | 11.33 | 14.73 | 21.09 | 25.31 |
 | Random coil (%) | 1645-1640 | 37.50 | 27.30 | 3.28 | 5.52 |
 | α-Helix (%) | 1657-1648 | 16.96 | 25.52 | 49.40 | 31.03 |
 | 3-Turn helix (%) | 1666-1659 | 20.13 | 27.63 | 21.35 | 34.54 |
 | Antiparallel β-sheet/ aggregated strands (%) | 1680-1695 | 12.53 | 3.62 | 2.38 | 1.59 | </md>


[User] <|image|>Parse the table content behind with markdown code: <md> | Rank | R | G | B | FOV | Contrast | Fmeasure | Positional Error

[Assistant]
(mm) | Angular Error (°) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 195 | 120 | 75 | narrow | 4 | 1.00 | 0.60 | 3.1 |
 | 2 | 240 | 45 | 75 | narrow | 3 | 1.00 | 0.92 | 3.0 |
 | 3 | 105 | 30 | 150 | narrow | 4 | 1.00 | 1.15 | 2.9 | </md>


[User] <|image|>Translate the table into Markdown format.

[Assistant]
<md> | Variable | % of TIP cases(N = 45) | % of controlsa(N = 137) | ORcrude(95% CI) | ORadj(95% CI) |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Days before seeking treatment |
 | 0–3 | 29 | 63 | ref |  |
 | 4–9 | 42 | 32 | 3.0(1.8–5.7) | 2.2(0.83–5.8) |
 | 10+ | 29 | 5.1 | 13(3.8–43) | 11(1.9–61) |
 | <COLSPAN=5> Heard of typhoid fever before |
 | Yes | 64 | 82 | ref |  |
 | No | 36 | 18 | 2.5(1.0–5.9) | NS |
 | <COLSPAN=5> Heard of typhoid outbreak in Kampala |
 | Yes | 41 | 75 | ref |  |
 | No | 59 | 25 | 4.4(1.9–10) | 5.2(1.8–15) |
 | <COLSPAN=5> Got treatment beforeb |
 | No | 45 | 77 | ref |  |
 | Yes | 96 | 23 | 7.0(1.5–31) | 9.0(1.1–78) | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Name | Sequence | Use |
 | --- | --- | --- |
 | hepP-For1 | GGACTGGCAAGCTGATAGGA | Analysis of hepP transcriptionAnalysis of operon |
 | hepP-Rev1 | CGATACGCAAGGAAAGAGGA | Analysis of hepP transcriptionAnalysis of operon |
 | zbdP-For1 | CGGGTGTTGGCTATTGATTT | Analysis of zbdP transcription |
 | zbdP-Rev1 | AACAATCCGTCCACGCTTAC | Analysis of zbdP transcription |
 | zbdP-For2 | CTTCTGAGGACAAGGCTTCG | Analysis of operon |
 | hepP-Rev2 | GATAAGGCTCCCAACCTTC | Analysis of operon |
 | zbdP-For3 | AGCCGACTATCGCTTGTGAA | Confirmation of hepP mutation |
 | hepP-Rev3 | GTGCTTTTCGAGCAATGGAG | Confirmation of hepP mutation |
 | hepP-ATG | ATGGCACTTCAAAAACTCGTCCG | Cloning hepP |
 | hepP-[-TGA] | ACTCGTATTTGCTGGGGTGGAATT | Cloning hepP |
 | Trx Forward | TTCCTCGACGCTAACCTG | Confirmation of cloning |
 | pBAD Reverse | GATTTAATCTGTATCAGG | Confirmation of cloning |
 | hepP-For2 | CGCTGGTGCAACAAGTAGAA | Analysis of hepP transcription |
 | hepP-Rev4 | GCGTGATACATCGGAGACAA | Analysis of hepP transcription | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Protein | Case A | Case B | Case C | Case D | Case E |
 | --- | --- | --- | --- | --- | --- |
 | CA I | -6.5 | -1.6 | -3.3 | -4.3 | -2.6 |
 | CA II | -2.6 | -1.3 | -26 | -4.3 | -13 |
 | FOV | -13 | -13 | -26 | * | -26 |
 | MnSOD | +1.7 | -2.6 | +6.5 | +1.4 | +1.1 |
 | HMG-1 | +13 | * | +3.7 | +13 | * |
 | PGK1 | +1.6 | +1.1 | -1.2 | +2.6 | -1.4 |
 | AST | -13 | -1.6 | -6.5 | -3.7 | -2.6 |
 | GST | * | -26 | * | -13 | -13 | </md>


[User] <|image|>Convert the table into Markdown format.

[Assistant]
<md> |  | Athlete | N | Mean | Std Deviation | Std Error Mean |
 | --- | --- | --- | --- | --- | --- |
 | Total Deviation(right hand) | yes | 83 | 80.0 | 14.9 | 3.3 |
 |  | no | 217 | 73.3 | 14.4 | 1.6 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  | <COLSPAN=2> LRFS | <COLSPAN=2> PFS | <COLSPAN=2> OS |
 |  | HR(95%CI) | P | HR(95%CI) | P | HR(95%CI) | P |
 | --- | --- | --- | --- | --- | --- | --- |
 | Age >60 | 1.858(0.942-3.667) | 0.074 | 1.845(0.986-3.450) | 0.055 | 2.595(1.233-5.461) | 0.012 |
 | ELTI | 1.467(0.810-2.655) | 0.206 | 1.715(0.987-2.978) | 0.056 | 2.426(1.102-5.342) | 0.028 |
 | 3DCRT | 2.230(1.027-4.845) | 0.043 |

[Assistant]
1.544(0.800-2.981) | 0.195 | 2.104(0.832-5.323) | 0.116 |
 | CR after chemotherapy | 0.430(0.214-0.866) | 0.018 | 0.475(0.255-0.885) | 0.019 | 0.486(0.210-1.036) | 0.091 |
 | Asparaginase-based chemotherapy | 0.448(0.172-1.169) | 0.101 | 0.424(0.184-0.981) | 0.045 | 0.440(0.136-1.424) | 0.171 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Property | <COLSPAN=6> A Type of Polymer Concrete |
 | CG-0 | CG-10 | CG-30 | CG-50 | CG-70 | CG-100 |
 | --- | --- | --- | --- | --- | --- | --- |
 | Bulk density [g/cm3] | 1.86 | 1.89 | 1.93 | 1.93 | 1.94 | 2.04 |
 | Water adsorption [%] | 1.55 | 1.53 | 1.49 | 1.46 | 1.37 | 1.22 |
 | Water resistance | <COLSPAN=6> above W6 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | <ROWSPAN=2>  | <ROWSPAN=2> Objects | <COLSPAN=2> Horizontal Rectification | <COLSPAN=2> Commonly Used Methods |
 | Integrity (%) | Precision (RMSE) | Integrity (%)

[Assistant]
| Precision (RMSE) |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Horizontal Objects | Roof 1 | 99.15% | 10.1 cm | 98.89% | 15.2 cm |
 | Roof 2 | 98.86% | 18.1 cm | 98.55% | 21.5 cm | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | Phage name | Place isolated | Capsid height (nm) | Capsid width (nm) | Tail length (nm) | Tail width (nm) | Contracted sheath length (nm) | Contracted sheath width (nm) |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Myoviridae |  |  |  |  |  |  |  |
 | Abouo | Utah, USA | 68.3 ± 5.6 | 65.1 ± 3.6 | 113.6 ± 2.6 | 12.7 ± 3.8 | 45.7 ± 5.0 | 24.0 ± 2.3 |
 | Davies | Utah, USA | 68.1 ± 4.5 | 61.7 ± 3.2 | 125.4 ± 0.2 | 9.8 ± 0.7 | 83.0 ± 0 | 19.2 ± 0 |
 | Emery | Utah, USA | 73.5 ± 3.2 | 66.0 ± 3.3 | 162.2 ± 5.2 | 11.0 ± 1.4 | 82.9 ± 0 | 25.5 ± 0 |
 | Jimmer1 | Utah, USA | 68.2 ± 3.6 | 61.3 ± 3.9 | 98.9 ± 14.7 | 11.9 ± 1.4 | 43.1 ± 1.5 | 23.3 ± 2.5 |
 | Jimmer2 | Utah, USA | 62.9 ± 2.5 | 66.3 ± 2.2 | 75.6 ± 8.7 | 7.7 ± 0.3 | 42.9 ± 2.4 | 20.6 ± 0.4 |
 | PBL0.5c* (and PBL2 *) | Georgia (Minnesota) | 66.3 ± 3 | 66.3 ± 3 | 142.0 ± 1 | 9.2 ± 0.9 | 92.0 ± 1 | 22.5 ± 1.2 |
 | BL2* | Unknown | 64.1 ± 1.1** | 60.1 ± 3.9** | 116 | 7 | 76 | 19 |
 |

[Assistant]
Siphoviridae |  |  |  |  |  |  |  |
 | phiIBB_Pl23* | Portugal | <COLSPAN=4> Not published |  |  |
 | Round capsid |  |  |  |  |  |  |  |
 | PBL3* | USA | 62.2 ± 2.2** | 70 ± 2.1 | 140 ± 2.8 | 10.1 ± 0.9 | — | — |
 | Elongated capsid |  |  |  |  |  |  |  |
 | BLA* | Czechoslovakia | 150 | 68 | 280 | 13 | — | — |
 | PBL1* (and PPL1c *) | USA | 95.9 ± 2.6 | 52.5 ± 1.9 | 131.8 ± 1.5 | 9.4 ± 0.6 | — | — | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> |  | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
 | --- | --- | --- | --- | --- |
 | WBC (X 1000) | 3.0 to < 4.0 | 2.0 to < 3.0 | 1.0 to < 2.0 | < 1.0 |
 | Platelets (X 1000) | 75 to 100 | 50 to <75 | 25 to < 50 | <25 or spontaneous |
 | Neutrophils (X 1000)

[Assistant]
| 1.5 to 1.9 | 1.0 to < 1.5 | 0.5 to < 1.0 | <0.5 or sepsis |
 | Hemoglobin (GM %) | 11 to 9.5 | <9.5 to 7.5 | <7.5 to 5.0 | < 5.0 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Socioeconomic factors | ORa (95% CI)Model 1b | AOR (95% CI)Model 2c | AOR (95% CI)Model 3d |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Education |
 | Illiteracy and primary | 2.9 (1.1–7.6) | 2.0 (0.5–7.8) | 1.6 (0.4–6.2) |
 | Secondary and higher | 1.00 | 1.00 | 1.00 |
 | <COLSPAN=4> Family income |
 | Low | 3.4 (1.3–9.0) | 1.1 (0.2–4.9) | 1.4 (0.3–5.7) |
 | Medium and high | 1.00 | 1.00 | 1.00 |
 | Nationality |  |  | – |
 | Afghan | 6.3 (1.7–23.9) | 4.4 (1.1–18.2) |  |
 | Iranian | 1.00 | 1.00

[Assistant]
|  |
 | Insurance | 0.2 (0.1–0.6) | – | – |
 | Insurance-nationality |  | – |  |
 | Uninsured Afghan | 7.3 (1.9–28.3) |  | 5.1 (1.2–22.6) |
 | Uninsured Iranian | 2.0 (0.5–7.9) |  | 1.7 (0.4–7.1) |
 | Insured Iranian | 1.00 |  | 1.00 | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> RLG (N = 11) | <COLSPAN=2> NRG (N = 12) | <COLSPAN=2> NCG (N = 5) | <COLSPAN=2> CG (N = 30) |
 |  | M | SD | M | SD | M | SD | M | SD |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=9> T1 |
 | Age | 25.09 | 6.47 | 25.25 | 4.09 | 29.6 | 4.88 | 26.17 | 5.69 |
 | Education | 14.27 | 1.62 | 14.25 | 1.96 | 13 | 1.41 | 14.03 | 1.65 |
 | Males/Females | 3/8 |  | 10/2 |  | 1/4 |  | 14/14 |  |
 | IQ | 115.46 | 6.53 | 119.08 | 9.65 | 123.4 | 7.57 | 120.97 | 8.23 |
 | Months depressed | 1.64 | 1.57 | 2.08 | 2.07 | 2 | 0.71 | * |  |
 | MADRS score | 25 | 4.36 | 23 | 2.49 | 28 | 3.16 | * |  |
 | Treatment | <COLSPAN=8> Frequency/percent |
 | Psychological treatment. | 2 | 18.2% | 5 | 41.7% | 1 | 20% | * |  |
 | Medical treat. | 1 | 9.1% | 1 | 8.3% | 2 | 40% | * |  |
 | Both psych/med. | 6 | 54.5% | 4 | 33.3% | 0 |  | * |  |
 | No treatment | 2 | 18.2% | 2 | 16.7% | 2 | 40% | * |  |
 | <COLSPAN=9> T2 |
 | MADRS score | 9.09 | 5.19 | 7.42 | 3.53 | 18 | 6.33 | * |  |
 | Treatment | <COLSPAN=8> Frequency/percent |
 | Psychological treatment. | 3 | 27.3% | 1 | 8.3% | 1 | 20% | * |  |
 | Medical treatment | 1 | 9.1% | 0 |  | 1 | 20% | * |  |
 | Both psych/med.treat. | 4 | 36.4% | 6 | 50% | 1 | 20% | * |  |
 | No treatment | 3 | 27.3% | 5 | 41.7% | 2 | 40% | * |  | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> |  | No of patients |
 | --- | --- |
 | Gender: |  |
 | Men | 24 |
 | Women | 26 |
 | Age (years): |  |
 | 30-39 | 2 |
 | 40-49 | 8 |
 | 50-59 | 15 |
 | 60-69 | 16 |
 | 70-79 | 6 |
 | ≥ 80 | 3 |
 | Tumor site: |  |
 | Bladder | 4 |
 | Breast | 10 |
 | Colorectal | 4 |
 | Esophageal | 9 |
 | Gynecological | 7 |
 | Lung | 6 |
 | Prostate | 10 |
 | <COLSPAN=2> Length of interval between baseline and follow-up interview |
 | (median) |  |
 | < 50 days | 22 |
 | ≥ 50 days | 28 | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> |  | Alfentanil group (n=129) | Fentanyl group (n=131) | P value |
 | --- | --- | --- | --- |
 | Cardiopulmonary complications | 14 (10.9) | 14 (10.7) | 0.966 |
 | Systolic hypotension (<90mmHg) | 12 (9.3) | 11 (8.4) | 0.797 |
 | MAP decreased >25% | 4 (3.1) | 2 (1.5) | 0.445 |
 | Use of vasopressors | 1 (0.8) | 2 (1.5) | 0.445 |
 | Bradycardia (<50 beats/min) | 0 | 0 | 0.445 |
 | Hypoxemia (SpO2 < 90%) | 4 (3.1) | 3 (2.3) | 0.721 |
 | Chin lift | 4 (3.1) | 1 (0.8) | 0.212 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Population | Disability | Intervention | Study type/outcome measures (economic evidence searches only) |
 | --- | --- | --- | --- |
 | Child* | Disab* | Wheelchair | Cost benefit |
 | Adolescen* | Physically impair* | Buggy | Cost utility |
 | Young* | Physical impair* | Mobility technolog* | Cost effective* |
 | Teen* | Handicap* | Mobility aid | Qaly |
 | Disab* child* | Dystroph* | Powered wheelchair | Quality-adjusted life year |
 | Disab* | Cerebral palsy | Mobility equipment | Quality adjusted life year |
 | Adolescen* | Spina bifida | Motorised | Health economic* |
 | Disab* young* | Wheelchair* | Mobility training | Economic analys* |

[Assistant]
 | Disab* teen* | Special needs | Wheelchair service | Cost minimisation |
 |  | Amputee | Electric scooter | Health care cost* |
 |  | Complex needs | Pushchair | Healthcare cost* |
 |  | Brain injury | Mobility | Social economic* |
 |  | Brain damage* |  | Social care economic* | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> |  | DMFT | D | M | F |
 | --- | --- | --- | --- | --- |
 | Our study |  |  |  |  |
 | 35–44 | 14.5 | 5.0 | 3.0 | 6.4 |
 | 65-74

[Assistant]
| 22.6 | 4.2 | 15.4 | 3.0 |
 | French population (1995) |  |  |  |  |
 | 35–44 means | 14.6 | 1.2 | 3.0 | 10.4 |
 | High occupational group (OG) | 13.7 | 0.9 | 2.0 | 10.8 |
 | Low OG | 14.8 | 1.3 | 3.6 | 9.9 |
 | 65-74 means | 23.3 | 1.1 | 16.9 | 5.2 |
 | High OG | 19.4 | 0.9 | 10.2 | 8.4 |
 | Low OG | 24.5 | 1.2 | 19.4 | 4.0 | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | Locus tag | Gene symbol | Description | Relative fold change in 4-APP-treated to vehicle-treated C57BL/6 mice (mean (s.e.)) | Relative fold change in MyD88-deficient to wild type C57BL/6 mice (mean (s.e.)) |
 | --- | --- | --- | --- | --- |
 | SAOUHSC_02265 | agrA | Accessory gene regulator protein A | −1.60 (0.22) | −1.62 (0.5) |
 | SAOUHSC_02566 | sarR | Accessory regulator R | −1.83 (0.22) | −1.23 (0.09) |
 | SAOUHSC_01121 | hla | Alpha-hemolysin | −3.32 (1.56) | −18.06 (0.16) |
 | SAOUHSC_02971 | aur | Zinc metalloproteinase aureolysin | −2.31 (0.96) | −2.59 (0.75) |
 | SAOUHSC_00988 | sspA | Glutamyl endopeptidase | −2.19 (0.01) | −2.32 (0.46) |
 | SAOUHSC_00561 | vraX | Protein VraX | −3.91 (2.76) | 1.11 (0.04) |
 | SAOUHSC_00436 | gltD | Glutamate synthase subunit beta | −2.41 (1.11) | −6.03 (1.66) |
 | SAOUHSC_01803 | aapA | D-serine/D-alanine/glycine transporter | 1.21 (2.32) | 1.69 (0.29) |
 |  | RNAIII | Regulatory RNA | −1.80 (0.53) | −2.52 (0.08) | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Univariate Analysis | <COLSPAN=2> Multivariate Analysis |
 | Variable | HR (95% CI) | p-value | HR (95% CI) | p-value |
 | --- | --- | --- | --- | --- |
 | Age > 65 | 1.44 (0.64–2.43) | 0.58 | NA | NA |
 | Male sex | 2.23 (1.42–3.05) | 0.01 | 3.66 (1.56–8.60) | 0.002 |
 | G3 vs G1G2 vs G1 | 1.36 (0.58–3.21)0.33 (0.03–2.92) | 0.290.32 | NA | NA |
 | T3-T4 vs T1-T2 | 1.94 (0.88–4.25) | 0.12 | NA | NA. |
 | N + ve vs N -ve | 2.11 (1.31–2.90) | 0.02 | 2.25 (1.00–5.17) | 0.049 |
 | RT total dose | 1.42 (0.87–2.33) | 0.16 | NA | NA |
 | Boost: yes vs no | 1.72 (0.40–7.35) | 0.47 | NA | NA |
 | OTT > 42 days | 1.75 (0.86–2.65) | 0.19 | NA | NA |
 | Hb | 0.5 (0.30–0.83) | 0.006 | 0.53 (0.33–0.87) | 0.001 |
 | Response | 6.26 (2.73–14.40) | < 0.0001 | 6.96 (2.96–16.50) | < 0.0001 | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Databases(update search to mid Oct 2010) | Search Terms | Hand Search of Journals (update search to mid Oct 2010) |
 | --- | --- | --- |
 | Web of Knowledge all databases(Web of Science with conferenceProceedings (1899-2010), BIOSISPreviews (1969-2010), Inspec(1969-2010), MEDLINE (1950-2010),Journal Citation Reports (2000-2010));OVID (AMED (1985-2010); MEDLINE(1950 to 2010); PsycINFO (1806 to 2010);and EMBASE (1980 to 2010)); Cancerlit(1975-2010); ASSIA (1987-2010);CINAHL (1982 to 2010); and Cochranereviews (1996-2010). | ("United Kingdom" OR UK OR Britain OREngland OR Wales OR Scotland OR "NorthernIreland")AND(palliative OR terminal OR "end of life"OR end-of-life OR death OR dying OR"continu* care" OR "advance directive*"OR hospice* OR "supportive care")AND(cultur* OR intercultural OR cross-culturalOR transcultural OR ethnic* OR migrant* ORminorit* OR diversity OR Muslim* OR Jew* ORChristian* OR Sikh* OR Buddh* OR Hindu* ORIndia* OR Pakistan* OR black OR white ORCaribbean* OR Africa* OR Bangladesh* ORIrish OR British OR Chinese OR Asian*)a | European Journal of Palliative Care 1994-2010International Journal of Palliative Nursing 1996-2010Palliative Medicine 1987-2010Journal of Palliative Care 1985-2010Diversity in Health and Social Care 2004-2008(Diversity in Health and Care 2008-2010)Omega 1970-2010Mortality 1996-2010Medical Anthropology Volume 21 2002-2010 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Variables | N | HOMA-IR | P |
 | --- | --- | --- | --- |
 | Genotype | 92 |  |  |
 | Non-3 | 74 (80.4%) | 1.94 (1.51–3.61) | <ROWSPAN=2> 0.890 |
 | 3 | 18 (19.6%) | 1.93 (1.46–3.56) |
 | Fibrosis stage∗ | 89 |  |  |
 | F0/F1 | 63 (70.8%) | 1.93 (1.51–2.93) | <ROWSPAN=2> 0.207 |
 | F2/F3 | 26 (29.2%) | 2.75 (1.55–3.95) |
 | Viral load | 73 |  |  |
 | >400.000 UI/mL | 55 (75.3%) | 1.53 (1.17–2.35) | <ROWSPAN=2> 0.027 |
 | <400.000 UI/mL | 18 (24.7%) | 2.21 (1.29–3.76) | </md>


[User] <|image|>Convert the diagram into Markdown language.

[Assistant]
<md> |  | <COLSPAN=3> Dependent variables and model summaries |
 |  | <COLSPAN=2> Visuo-spatial WM (late) | <COLSPAN=2> Verbal WM (late) | <COLSPAN=2> Reasoning (late) |
 | Independent variables | β | P | β | P | β | P |
 | --- | --- | --- | --- |
 | Constant | – | 0.002 | – | 0.032 | – | 0.171 |
 | Sex | -0.568 | 0.242 | 0.300 | 0.422 | -0.025 | 0.612 |
 | Age (Inverse) | -150.70 | 0.241 | 57.692 | 0.517 | -20.47 | 0.145 |
 | Mother Edu (years) | 0.048 | 0.680 | -0.107 | 0.242 | 0.018 | 0.139 |
 | Father Edu (years) | 0.185 | 0.138 | 0.043 | 0.653 | -0.010 | 0.423 |
 | Outcome (Early) | 0.715 | <0.001 | 0.773 | <0.001 | 0.668 | <0.001 |
 | Online/gaming/TV(h/w) | -0.002 | 0.907 | 0.043 | 0.004 | 0.001 | 0.436 |
 | Exercise (h/w) | -0.229 | 0.078 | 0.157 | 0.110 | -0.005 | 0.712 |
 | Music (h/w) | 0.351 | 0.003 | 0.261 | 0.006 | 0.021 | 0.090 | </md>


[User]
<|image|>What are the following image content in markdown style: <md> |  | Male, n (%) | Female, n (%) | Total, n (%) |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Pathological stage |
 | I | 8 (13.6) | 51 (84.4) | 59 (61.5) |
 | II | 2 (40.0) | 3 (60.0) | 5 (5.2) |
 | III | 2 (11.0) | 16 (88.9) | 18 (18.8) |
 | IV | 2 (14.3) | 12 (85.7) | 14 (14.6) |
 | Total | 14 (14.6) | 82 (85.4) | 96 (100) |
 | <COLSPAN=4> Histology |
 | Adenocarcinoma | 11 (12.2) | 79 (87.8) | 90 (93.8) |
 | Squamous cell carcinoma | 3 (75.0) | 1 (25.0) | 4 (4.2) |
 | Small cell carcinoma | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 | Others | 0 (0.0) | 2 (100) | 2 (2.1) |
 | <COLSPAN=4> EGFR mutation status |
 | Positive | 5 (8.8) | 52 (91.2) | 57 (59.4) |
 | Exon 19 | 1 (4.3) | 22 (95.7) | 23 (24.0) |
 | L858R | 3 (12.0) | 22 (88.0) | 25 (26.0) |
 | Others | 1 (11.1) | 8 (88.9) | 9 (9.4) |
 |

[Assistant]
Negative | 9 (23.1) | 30 (76.9) | 39 (40.6) |
 | <COLSPAN=4> HPV genotyping status |
 | Positive | 0 (0.0) | 1 (100.0) | 1 (1.0) |
 | Negative | 14 (14.7) | 81 (85.3) | 95 (99.0) | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Calcium channel blockers | Limited to women currently using an antihypertensive drug for 5 years or more (N = 8057) | Limited to women currently using an antihypertensive drug for 10 years or more (N = 3879) |
 | --- | --- | --- |
 | Never used

[Assistant]
| Reference | Reference |
 | Former user | 0.87 (0.36–2.11) | 0.80 (0.20–3.24) |
 | Current user (<5 years) | 1.06 (0.71–1.58) | 1.09 (0.60–1.99) |
 | (5–10 years) | 1.14 (0.81–1.61) | 1.15 (0.58–2.29) |
 | (10+ years) | 0.89 (0.58–1.36) | 0.89 (0.57–1.40) | </md>


[User] <|image|>Encode the figure in Markdown syntax.

[Assistant]
<md> | Age (years) and sex | Spinal level | Score | Reason excised/cause of death |
 | --- | --- | --- | --- |
 | Normal tissue: live patients |  |  |  |
 | 18 M | L4/5 | 0 | Spinal trauma |
 |  | L5/S1 | 1 |  |
 | 24 M | L3/4 | 1 | Spinal trauma |
 | 48 F | L3/4 | 1 | Spinal reconstruction for metastatic breast cancer |
 | Normal tissue: cadaveric |  |  |  |
 | 59 F | L3/4 | 1 | Massive pulmonary embolism |
 | 52 M | L4/5 | 1 | Myocardial infarction |
 | 47 M | L3/4 | 1 | Road traffic accident |
 | 72 M | L3/4 | 1 | Myocardial infarction |
 | 64 M | L5/S1 | 2 | Myocardial infarction |
 | 75 F | L4/5 | 2 | CVA |
 | 47 F | L4/5 | 3 | Ovarian cancer |
 | 58 M | L4/5 | 3 | Myocardial infarct |
 | Degenerate tissue: live patients |  |  |  |
 | 51 M | L4/5 | 7 | Disc degeneration |
 | 60 M | L4/5 | 7 | Disc degeneration |
 | 25 M | L4/5 | 8 | Disc degeneration |
 | 45 M | L4/5 | 8 | Disc degeneration |
 | 48 M | L4/5 | 8 | Disc degeneration |
 | 73 F | L3/4 | 9 | Disc degeneration |
 | 61 M | L5/S1 | 9 | Disc degeneration |
 | 45 F | L5/S1 | 9 | Disc degeneration |
 | 53 M | L4/5 | 10 | Disc degeneration |
 | 46 F | L4/5 | 11 | Data not available |
 | Degenerate tissue: cadaveric |  |  |  |
 | 49 F | L4/5 | 5 | Data not available |
 | 57 F | L4/5 | 6 | Myocardial infarction |
 | 64 M | L4/5 | 7 | Myocardial infarction |
 | 69 M | L4/5 | 8 | CVA |
 | 47 F | L3/4 | 8 | Breast cancer |
 | 76 M | L4/5 | 9 | CVA |
 | 50 M | L3/4 | 9 | Myocardial infarction |
 | 61 F | L5/S1 | 10 | Data not available |
 | 28 M | L4/5 | 11 | Road traffic accident |
 | 59 M | L4/5 | 11 | Myocardial infarction | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | clinic phenotype | number of samples | HCMV PCR positive samples |
 | --- | --- | --- |
 | poorly differentiated adenocarcinomas | 7 | 0 |
 | moderately differentiated adenocarcinomas | 24 | 5 |
 | well differentiated adenocarcinomas | 5 | 0 |
 | adenomas | 20 | 1 |
 | total | 56 | 6 | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | b-DNACp-MBs-Mixture Solution Incubation Time, min | [Anti DNA–RNA Hybrid Antibody], μg·mL−1 | [ProtA–HRP40], μg·mL−1 | Slope, nA·nM−1 | Sensitivity, % |
 | --- | --- | --- | --- | --- |
 | 30 | 2.0 | 2.0 | 55,214 ± 921 | 100 |
 | <ROWSPAN=4> 15 | 2.0 | 2.0 | 34,843 ± 2542 | 63.1 |
 | 4.0 | 2.0 | 30,844 ± 4494 | 55.9 |
 | 2.0 | 4.0 | 53,899 ± 659 | 97.6 |
 | 4.0 | 4.0 | 48,862 ± 4269 | 88.5 | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | miRNA_name | Rank sum rank |
 | --- | --- |
 | rno-miR-92a | 1 |
 | rno-miR-25 | 2 |
 | rno-miR-27a | 3 |
 | rno-miR-92b | 4 |
 | rno-let-7b* | 5 |
 | rno-miR-93 | 6 |
 | rno-miR-130b | 7 |
 | rno-miR-320 | 8 |
 | rno-miR-874 | 9 |
 | rno-miR-24 | 10 |
 | rno-miR-127* | 211 |
 | rno-miR-22 | 212 |
 | rno-miR-101a | 213 |
 | rno-miR-138 | 214 |
 | rno-miR-98 | 215 |
 | rno-miR-532-3p | 216 |
 | rno-miR-331 | 217 |
 | rno-miR-434* | 218 |
 | rno-miR-329* | 219 |
 | rno-miR-7a | 220 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | <COLSPAN=3> Residues | Most favored (%) | Allowed regions (%) | Generously allowed (%) | Disallowed (%) |
 | --- | --- | --- | --- | --- | --- | ---

[Assistant]
|
 | <ROWSPAN=4> m35kDa | <ROWSPAN=2> Pre-MD | Procheck | 61.6 | 29.8 | 6.2 | 2.5 |
 | MolProbity | 69.9 | 20.4 | - | 9.7 |
 | <ROWSPAN=2> Post-MD | Procheck | 74.0 | 22.3 | 2.9 | 0.8 |
 | MolProbity | 86.0 | 12.7 | - | 1.3 |
 | <ROWSPAN=4> m78kDa | <ROWSPAN=2> Pre-MD | Procheck | 76.6 | 16.9 | 3.8 | 2.7 |
 | MolProbity | 80.7 | 11.7 | - | 7.6 |
 | <ROWSPAN=2> Post-MD | Procheck | 73.3 | 20.3 | 4.5 | 2.0 |
 | MolProbity | 84.1 | 12.7 | - | 3.2 |
 | <ROWSPAN=4> m87kDa | <ROWSPAN=2> Pre-MD | Procheck | 72.1 | 20.5 | 5.0 | 2.4 |
 | MolProbity | 78.5 | 12.8 | - | 8.7 |
 | <ROWSPAN=2> Post-MD | Procheck | 74.3 | 21.3 | 2.8 | 1.6 |
 | MolProbity | 83.5 | 12.7 | - | 3.8 | </md>


[User] <|image|>Translate the image into Markdown format.

[Assistant]
<md> | Characteristics | Nonprogressors (n = 21) | Progressors (n = 46) |
 | --- | --- | --- |
 | Gender, male (%) | 14 (67) | 30 (65) |
 | Age, years | 40.1 (1.1) | 39.9 (1.1) |
 | BMI, kg/m2 | 22.9 (0.2) | 23.1 (0.2) |
 | Systolic blood pressure, mm Hg | 119.9 (2.7) | 115.9 (1.9) |
 | Diastolic blood pressure, mm Hg | 79.6 (1.4) | 77.3 (1.3) |
 | Smoking, n (%) | 13 (62) | 30 (65) |
 | TDF-FTC-based therapy, n (%) | 7 (33) | 28 (61)* |
 | CD4+ T cell count, cells/μL | 463.2 (46.1) | 469.9 (19.3) |
 | Total cholesterol, mmol/L | 4.79 (0.3) | 5.02 (0.4) |
 | HDL cholesterol, mmol/L | 1.18 (0.2) | 1.17 (0.1) |
 | LDL cholesterol, mmol/L | 2.66 (0.3) | 2.79 (0.4) |
 | Triglycerides, mmol/L | 2.48 (0.3) | 2.51 (0.3) |
 | Glucose, mmol/L | 5.40 (0.4) | 5.41 (0.4) |
 | Delta IMT, mm | −0.05 (0.01) | 0.22 (0.01)* | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | principle tasks | learning objectives |
 | --- | --- |
 | - Pre-marital & health-care services. | - Take proper family, medical history, educate couples about the essentials, order for CXR, blood group, R.H & other investigations for STD.- Take proper obstetric history, conduct properly clinical examination searching for signs of anemia hypertension, edema, urinary tract disorders, pelvic size and shape, and any fetal abnormality, do a schedule for antenatal visit and weight checking giving antitetanus toxoid at the proper time & calculate the expected date for delivery. |
 | - Management of common gestational health problems. | - Diagnose and prescribe treatment for anemia, hypertension, urinary tract infections, toxoplasmosis and diabetes, and follow up patients through out gestational period. |
 | Risky pregnancies – diagnosis and follow up. | - Detect and manage risky pregnancies and follow them up. |
 | Delivery-health-care services. | - Facilitate process of delivery to be normal uncomplicated vaginal labor and promote uterine contractions for expulsion of a head presented fetus under sterile conditions. |
 | Essential postnatal health care services. | - Examine for unevoluted uterus, bleeding & promote healthy purperium, lactation and look for breast complications including over encouragement or crackled nipples. |
 | - Health educational advice for pregnant and lactating women. | - Use proper methods of communication to explain essential nutrient materials needed and the value of attending MCH clinics periodically, taking tonic drugs, vaccination and care of breasts. |
 | - Immunization of women during the age of child bearing. | - Protect women through proper implementing of vaccination program against German measles and tetanus. |
 | - Referral services. | - Put criteria for risky patient's referral and direction, identify proper time and essential measures for referral, and follow up referred patients. |
 | - Screening for the risk of developing breast carcinoma. | - Perform a proper clinical examination of breasts and detect any lump and manage accordingly specially for those with positive family history of breast cancer. |
 | - Follow up hydatiform-mole | - Monitor women with history of hydatidiform mole, prescribe essential contraceptive, give methotrexate, and follow them up. |
 | - Management of common health problems of lactating breast. | -

[Assistant]
Diagnose and manage common breast problems e.g. crackled nipples, retracted malformed nipples, and breast abscess. |
 | - Infertility and menstrual cycle regulation measures. | - Take proper menstrual history, detect any abnormality, relate findings to failure of conception, and suggest proper treatment method. |
 | - Family planning services. | - Display a proper action for a better child spacing time, and communicate properly to justify a routine attendance of family planning clinics. | </md>


[User] <|image|>Convert the picture to Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=2> Incidents of violent reoffending | <COLSPAN=3> Adjusted hazard ratio* |
 |  | Without substance use disorder | With substance use disorder | Without substance use disorder | With substance use disorder | p value for interaction† |
 | --- | --- | --- | --- | --- | --- |
 | Any psychiatric disorder‡ | 764/3426 (22%) | 1912/5504 (35%) | 1·39 (1·29–1·50) | 2·43 (2·30–2·57) | 0·85 |
 | Schizophrenia spectrum disorder | 66/303 (22%) | 390/934 (42%) | 1·29 (1·00–1·67) | 2·68 (2·41–2·98) | 0·44 |
 | Bipolar disorder | 11/72 (15%) | 41/144 (28%) | 1·45 (0·75–2·79) | 3·22 (2·35–4·39) | 0·67 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> |  | <COLSPAN=2> Univariate | <COLSPAN=2> Multivariate |
 | Characteristic | ORa (95% CI) | p-valueb | AORc (95% CI) | p-value |
 | --- | --- | --- | --- | --- |
 | Older Age |  |  |  |  |
 | Per year older | 1.01 (0.98 - 1.04) | 0.446 |  |  |
 | Gender |  |  |  |  |
 | Female vs. Male | 2.25 (1.38 - 3.68) | 0.001 | 2.11 (1.26 - 3.55) | 0.005 |
 | Aboriginal Ancestry |  |  |  |  |
 | Yes vs. No | 1.87 (1.15 - 3.05) | 0.011 | 1.61 (0.96 - 2.72) | 0.072 |
 | Limited Access to Private Space d |  |  |  |  |
 | Yes vs. No | 1.63 (0.94 - 2.84) | 0.083 |  |  |
 | Drug Scene Exposure d |  |  |  |  |
 | Yes vs. No | 1.74 (1.12 - 2.72) | 0.014 | 1.40 (0.86 - 2.28) | 0.181 |
 | Most Drug Use in Public Areas d |  |  |  |  |
 | Yes vs. No | 1.69 (1.08 - 2.65) | 0.022 | 1.39 (0.85 - 2.28) | 0.187 |
 | Daily Crack Cocaine Smoking d |  |  |  |  |
 | Yes vs. No | 1.51 (0.96 - 2.35) | 0.071

[Assistant]
|  |  |
 | Binge Drug Use d |  |  |  |  |
 | Yes |  |  |  |  |
 | Risky Pipe Sharing* d |  |  |  |  |
 | Yes vs. No | 5.87 (1.79 - 30.29) | <0.001 | 5.50 (1.63 - 18.56) | 0.006 |
 | Encounters with Police e |  |  |  |  |
 | Yes vs. No | 2.08 (1.22 - 3.53) | 0.006 | 2.09 (1.20 - 3.65) | 0.010 |
 | Victim of Violence d |  |  |  |  |
 | Yes vs. No | 0.88 (0.51 - 1.52) | 0.648 |  |  | </md>


[User] <|image|>Convert the picture to Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2> Increase factor | <COLSPAN=2> 2-year-olds (n = 144) | <COLSPAN=2> 5-year-olds (n = 146) |
 | Freq | Percent (95% CI) | Freq | Percent (95% CI) |
 | --- | --- | --- | --- | --- |
 | <2.00 | 42 | 29.2% (21.9, 37.3) | 63 | 43.2% (35.0, 51.6) |
 | 2.00–2.99 | 12 | 8.3% (4.4%, 14.1) | 15 | 10.3% (5.9%, 16.4%) |
 | 3.00–3.99 | 14 | 9.7% (5.4, 15.8) | 9 | 6.2% (2.9, 11.4) |
 | ⩾4.00 | 76 | 52.8% (44.3, 61.2) | 59 | 40.4% (32.4, 48.8) | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | Group | Dose(μg mL−1) | NO(μmol/L) | NOS(U/mL) | iNOS(U/mL) |
 | --- | --- | --- | --- | --- |
 | Normal control | - | 56.94 ± 5.73 ** | 1.92 ± 0.30 ** | 0.64 ± 0.20 * |
 | STZ model | - | 89.34 ± 5.12 | 3.01 ± 0.35 | 1.00 ± 0.23 |
 | <ROWSPAN=3> SES | 100 | 76.79 ± 4.42 ** | 2.50 ± 0.25 * | 0.86 ± 0.28 |
 | 200 | 63.83 ± 5.26 ** | 2.21 ± 0.35 * | 0.75 ± 0.30 |
 | 400 | 58.43 ± 3.31 ** | 2.10 ± 0.18 ** | 0.61 ± 0.20 * | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Region | Population | Number of health districts | Number of health facilities (public and private) | Number of public health facilities | Rate health facilities/ population | Coverage rate DTP3 (2011), % |
 | --- | --- | --- | --- | --- | --- | --- |
 | Centre* | 3,525,664 | 29 | 571 | 370 | 1/6174 | 82 |
 | Far North | 3,480,414 | 28 | 308 | 260 | 1/11,300 | 84 |

[Assistant] | Total Cameroon | 19,406,110 | 2648 | 2648 | 1 888 | 1/7328 | 86 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> | <COLSPAN=2> Exclusion criteria for both HEPATICUS-1 and HEPATICUS-2 |
 | --- | --- |
 | <COLSPAN=2> Patients, whose mortality approaches 100%, or who are not likely to benefit from treatment(intervention with ADVOS is likely to be futile) |
 | <COLSPAN=2> Patients, whose current medical condition does not allow treatment with any extracorporeal procedure |
 | <COLSPAN=2> Potential conflict with good clinical practice (GCP) or with the declaration of Helsinki |
 | <COLSPAN=2> PaO2/FiO2 ≤ 100 mmHg (respiratory SOFA score of 4) |
 | <COLSPAN=2> Patient testament excludes the use of life-prolonging measures |
 | <COLSPAN=2> Post-operative patients whose liver failure is related to liver surgery |
 | <COLSPAN=2> Participation in another clinical study |
 | <COLSPAN=2> Patients diagnosed with Creutzfeldt-Jakob disease |
 | <COLSPAN=2> Pregnancy |
 | <COLSPAN=2> Weight ≥120 kg |
 | <COLSPAN=2> Uncontrolled seizures |
 | <COLSPAN=2> Mean arterial pressure ≤50 mmHg despite conventional medical treatment |
 | <COLSPAN=2> Active or uncontrolled bleeding |
 | <COLSPAN=2> Untreatable extrahepatic cholestasis |
 | <COLSPAN=2> Patients with MELD-score of 40 |
 | Exclusion criteria specific for HEPATICUS-1 | Exclusion criteria specific for HEPATICUS-2 |
 | Patients with creatinine >5 mg/dl or urine output <200 ml/day(renal SOFA-score of 4) | Patient with known history of chronic liver disease |
 | Patients who receive a vasopressor support of Dopamine >15 μg/kg/min or epinephrine >0.1 μg/kg/min or norepinephrine >0.1 μg/kg/min (cardiovascular SOFA-score of 4) |  | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> |  | Db/+, fed | Db/db, fed | Db/+, fasted | Db/db, fasted |
 | --- | --- | --- | --- | --- |
 | RR, ms | 124 ± 4 | 131 ± 3 | 137 ± 4 † | 154 ± 4*† |
 | HR, bpm | 483 ± 17 | 458 ± 12 | 438 ± 11 † | 390 ± 10*† |
 | SDRR, ms | 4.4 ± 1.0 | 5.0 ± 0.9 | 5.3 ± 0.8 | 6.0 ± 1.6 |
 | SD∆RR, ms | 2.1 ± 0.3 | 3.2 ± 0.6 | 2.8 ± 0.6 | 4.7 ± 0.7* |
 | pRR6,% | 3 ± 4 | 11 ± 5a | 8 ± 3 | 22 ± 6* |
 | LF Power, μs2 | 0.9 ± 0.2 | 0.9 ± 0.4 | 1.0 ± 0.4 | 2.5 ± 1.0 |
 | HF Power, μs2 | 2.4 ± 0.6 | 7.9 ± 3.8

[Assistant]
| 6.1 ± 3.4 | 15.4 ± 4.3a |
 | LF Power, % | 32 ± 4 | 17 ± 4 | 17 ± 4 | 15 ± 5 |
 | HF Power, % | 67 ± 4 | 84 ± 4 | 84 ± 4 | 86 ± 5 |
 | LF/HF | 55 ± 11 | 25 ± 10 | 24 ± 9 | 19 ± 4 |
 | n | 12 | 12 | 10 | 9 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Parameters | Mean ± SD |
 | --- | --- |
 | Age (years) | 58.41 ± 12.93 |
 | Time from onset of RRD to vitrectomy (days) | 12.07 ± 15.36 |
 | Range of RD (degrees) | 155.85 ± 86.67 |
 | Area of retinal break (pixels) | 37000 ±

[Assistant]
67100 |
 | hsa-miR-148a-3p (relative expression) | 23.68 ± 43.00 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Compound | A549 | HepG2 | PANC-1 |
 | --- | --- | --- | --- |
 | Curc. | 27.11 | 14.53 | 30.57 |
 | C501 # | 1.26 | 0.66 | 1.44 |
 | C502 | 2.39 | >5 | 2.20 |
 | C503 # | 1.70 | 2.55 | 1.66 |
 | C504 # | 1.58 | 1.24 | 1.40 |
 | C505 # | 1.29 | 1.48 | 1.43 |
 | C509 # | 2.27 | 2.98 | 1.01 |
 | C510 | >5 | 1.07 | >5 |
 | C513 | >5 | 3.11 | >5 |
 | C514 | inactive | inactive | inactive |
 | C515 # | 2.73 | 1.31 | 1.46 |
 | C516 | >5 | 4.19 | >5 |
 | C517 | >5 | >5 | 2.45 |
 | C518 # | 2.42 | 4.77 | 1.25 |
 | C519 | >5 | >5 | >5 |
 | C520 | inactive | inactive | inactive |
 | C521 # | 1.88 | 1.36 | 1.18 |
 | C524 # | 1.70 | 1.69 | 1.14 |
 | C525 | inactive | inactive | inactive |
 | C526 | inactive

[Assistant]
| inactive | inactive |
 | C529 | inactive | inactive | inactive |
 | C530 | inactive | inactive | inactive |
 | C532 | >5 | >5 | 1.58 |
 | C533 | >5 | 4.81 | >5 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <ROWSPAN=2>  | <COLSPAN=2> Ionic silver | <COLSPAN=2> Nanosilver |  |
 | Medium A | Medium E | Medium A | Medium E | Units |
 | --- | --- | --- | --- | --- | --- |
 | Chloride | 125 | 0.05 | 125 | 0.05 | mM |
 | Total silver in solution | 0.7–1 | 1–1.4 | 0.6 | 0.8–1.2 | μg/mL |

[Assistant]
| Dissolved silver | 6–130 | 0.5 | 1–2.5 | 0.5 | ng/mL |
 | Free silver | 1.3–1.8 | 3–9 | – | – | 10−10M |
 | Calc. free silver | 0.4–9 | 19 | 0.06–0.2 | 19–24 | 10−10M |
 | Toxicity floating | – | – | 0 | 0 | % |
 | Toxicity bottom | 30–90 | 10–60 | 40–60 | 10 | % | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Gene | Sequence (forward 5′- 3′) | Sequence (reverse 5′- 3′) |
 | --- | --- | --- |
 | Eta | AACCTGGCAACCATGAACTC | ATGAGGCTTTTGGACTGGTG |
 | Etb | CAGGATTCTGAAGCTCACCCTTT | TCCAAAACCAGCAAAAAACTCA |
 | Et-1 | TGTGCTCACCAAAAAGACAAGAA | GGTACTTTGGGCTCGGAGTTC |
 | Ece-1 | GCAAGAACATAGCCAGCGAG | CTCCGAGTATCTTCATCCATCC |

[Assistant]
| eNos | CATACTTGAGGATGTGGCTG | CCACGTTAATTTCCACTGCT |
 | Sma | TGACCCAGATTATGTTTGAGAC | AGAGTCCAGCACAATACCAG |
 | Ptgis | CATCAAACAGTTTGTGGTCCT | CAAAGCCATATCTGCTAAGGT |
 | Ptgir | CACGAGAGGATGAAGTTTACCA | AATCCTCTGATCGTGAGAGGC |
 | Tbxas1 | AGACTCAGGTTCCACTTCAG | TCACACCTGCCTTCTATGTC |
 | Tbxa2r | ACTGTGAGGTGGAGATGATGG | CAGGATGAAGACCAGCAAGG |
 | Actb | AGATGACCCAGATCATGTTTGAG | GTACGACCAGAGGCATACAG | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | <ROWSPAN=2> Data | <COLSPAN=2> SRNS | <COLSPAN=2> SSNS | <ROWSPAN=2> P value |
 | Number | % | Number | % |
 | --- | --- | --- | --- | --- | --- |
 | Hypertension | <COLSPAN=5>  |
 | Hypertensive | 16 | 59.3 | 2 | 7.4 | <ROWSPAN=2> 0.000 |
 | Normotensive | 11 | 40.7 | 25 | 92.6

[Assistant]
|
 | <COLSPAN=6> Hematuria |
 | Hematuria | 9 | 33.3 | 1 | 3.7 | <ROWSPAN=2> 0.005 |
 | No hematuria | 18 | 66.7 | 26 | 96.3 |
 | <COLSPAN=6> Renal insufficiency |
 | RI | 8 | 29.6 | 0.00 | 0.00 | <ROWSPAN=2> 0.002 |
 | No RI | 19 | 70.4 | 27 | 100 |
 | <COLSPAN=6> Mean s. albumin, g/L (mean ± SD) |
 | <COLSPAN=3> 2.400 ± 0.889 | <COLSPAN=2> 2.525 ± 0.867 | 0.601 |
 | <COLSPAN=6> Mean blood urea, mmol/L (mean ± SD) |
 | <COLSPAN=3> 6.499 ± 3.491 | <COLSPAN=2> 4.149 ± 1.405 | 0.002 |
 | <COLSPAN=6> Mean s. creatinine, mmol/L (mean ± SD) |
 | <COLSPAN=3> 79.518 ± 73.150 | <COLSPAN=2> 47.696 ± 14.904 | 0.031 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Cx26 type | <COLSPAN=2> Propidium iodide transfer (%) |  |
 |  | <2 min | 2~4 min | No transfer (%) |
 | --- | --- | --- | --- |
 | Cx26-WT | 13 (82.3) | 2 (12.5) | 1 (6.3) |
 | Cx26-V37I | 2 (12.5) | 3 (18.8)

[Assistant]
| 11 (68.8) |
 | Cx26-R75Q | 0 (0) | 2 (11.8) | 15 (88.2) |
 | Cx26-V37I+R75Q | 0 (0) | 3 (16.7) | 15 (83.3) | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> |  |  | <COLSPAN=2> δ-catenin |
 | --- | --- | --- | --- |
 | Sites | Total | Negative | Positive |
 | Supratentorial |  |  |  |
 | Hemisphere | 124 | 87(70.2%) | 37(29.8%) |
 | Diencephalon | 2 | 2(100%) | 0(0%) |
 | Total | 126 | 89(70.7) | 37(29.3%) |
 | Infratentorial |  |  |  |
 | Cerebellum | 17 | 13(76.5%) | 4(23.5%) |
 | Brain stem | 5 | 5(100%) | 0(0%) |
 | Spinal cord | 8 | 8(100%) | 0(0%) |
 | Total | 30 | 26(86.7%) | 4(13.3%)* | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Groups | Control | Let (PCOS) | Let+aloe combined | Aloe group | Metformin group |
 | --- | --- | --- | --- | --- | --- |
 | Serum Glutamate Pyruvate Transaminase (SGPT) mg/dl | 59.33±2.12 | 59.2±1.08 | 46.25±1.23 | 59.4±2.05 | 61±1.28 |
 | Creatinine mg/dl | 0.59±0.25 | 0.57±0.17 | 0.50±0.31 | 0.58±0.11 | 0.62±0.21 | </md>